Document:

EX-10.16

 Exhibit 10.16 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS 

BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM 

TO THE COMPANY IF PUBLICLY DISCLOSED 

SECOND AMENDMENT TO 
 THE
COLLABORATION AGREEMENT 
 This SECOND AMENDMENT (the “Second Amendment”) is made and entered into, effective as of December 6,
2019 (the “Second Amendment Effective Date”), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech SE, a European stock corporation
(“BNT”) (RNP and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F.
Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”). 

WHEREAS, the Parties entered into a Collaboration Agreement, dated as of September 20, 2016, as amended on June 1, 2018, pursuant to which BioNTech
and Genentech agreed to collaborate in the research, development, and commercialization of Collaboration Products (the “Agreement”). 

WHEREAS, BioNTech and Genentech wish to modify certain terms of the Agreement with respect to [***] (i) certain RNA manufacturing projects within the CMC
Development Plan and (ii) development of the commercial upstream manufacturing process. 
 NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	1.	 Defined Terms. 

 

	 	a.	 Section 1.20 is hereby deleted in its entirety and replaced with the following: 

“‘BioNTech Core Patents’ means (a) the Patents listed on Schedule 1.20, (b) [***] and
(c) all Patents claiming priority to any of the Patents described in clauses (a) or (b), or claiming priority to a priority document thereof.” 
  

	 	b.	 Section 1.27 is hereby amended by adding the following sentence to the end of the Section:

 “For clarity, BioNTech Know-How [***].” 

 

	 	c.	 Section 1.59 is hereby amended by adding the following clause to the end of the Section:

 “; provided, however, that, notwithstanding anything to the contrary in this Agreement or the MDSA,
Collaboration Know-How [***]” 

	 	d.	 The following definition is hereby added to the Agreement as Section 1.331: 

“‘External Sequencing Party’ means an entity other than BioNTech or Genentech that is selected by Genentech to conduct
some or all of the Sequencing Manufacturing Project.” 
  

	 	e.	 The following definition is hereby added to the Agreement as Section 1.332: 

“‘RNA Manufacturing Know-How’ means all
Know-How that is discovered, generated, conceived or reduced to practice by a Party (or any authorized Third Party acting on a Party’s behalf) solely or jointly in the course of conducting the RNA
Manufacturing Projects.” 
  

	 	f.	 The following definition is hereby added to the Agreement as Section 1.333: 

“‘RNA Manufacturing Projects’ means the work packages for the Collaboration Products concerning RNA manufacturing
process, [***] set forth in Schedule 1.333.” 
  

	 	g.	 The following definition is hereby added to the Agreement as Section 1.334: 

“‘Sequencing Manufacturing IP’ means the Sequencing Manufacturing Know-How and
all Patents that claim any such Sequencing Manufacturing Know-How.” 
  

	 	h.	 The following definition is hereby added to the Agreement as Section 1.335: 

“‘Sequencing Manufacturing Know-How’ means all
Know-How that is discovered, generated, conceived or reduced to practice by Genentech or by the External Sequencing Party on a Party’s behalf (whether solely or jointly with a Party) in the course of
conducting any activities in connection with the Sequencing Manufacturing Project.” 
  

	 	i.	 The following definition is hereby added to the Agreement as Section 1.336: 

“‘Sequencing Manufacturing Project’ means the development of the upstream portion of the Manufacturing Process for
Commercial Manufacturing [***].” 
  

	2.	 Exhibits. The schedule attached hereto as Exhibit A is hereby incorporated into the Agreement as
Schedule 1.333. 

  

	3.	 Amendment of the CMC Development Plan. For each RNA Manufacturing Project, the Parties hereby agree that
they will (a) agree upon a written project plan for such RNA Manufacturing Project, which will set forth the scope of work to be performed by each Party, deliverables, time schedule and budget (including required FTEs, equipment and other
resources), (b) promptly amend the CMC Development Plan to include such agreed-upon project plan for such RNA Manufacturing Project, and (c) conduct such RNA Manufacturing Project in accordance with such project plan.

  
 2 

	 	
Notwithstanding the foregoing, in the event that the Parties are unable to agree on such written project plan [***]. 

 

	4.	 Decision-Making. Section 2.8.2(g) is hereby amended by adding the following clause to the end of
the Section: 

 “[***]” 
  

	5.	 Sequencing Manufacturing by the External Sequencing Party. The following provision is hereby added to
the Agreement as Section 7.4: 

 “Sequencing Manufacturing by the External Sequencing Party.  

7.4.1    Sequencing Manufacturing Project. Notwithstanding anything to the contrary in this
Agreement (including Sections 7.1 and 7.2) or the MDSA, Genentech shall have the sole right and responsibility for the performance of the Sequencing Manufacturing Project, at its discretion (subject to Sections 7.4.2 and 10.2.5), and may use the
External Sequencing Party to conduct some or all of the Sequencing Manufacturing Project. Genentech shall ensure that the Sequencing Manufacturing Project is designed to deliver, and shall use commercially reasonable efforts to deliver, [***]. 

7.4.2    Use of External Sequencing Party by BioNTech. If in connection with BioNTech’s
Development of a BioNTech Indication or BioNTech’s Development or Commercialization of Reversion Products pursuant to Section 14.5.4, in each case, in accordance with (and subject to the terms and conditions of) this Agreement, BioNTech
desires to use the External Sequencing Party that Genentech is using to perform the sequencing for the upstream portion of the Manufacturing Process for Commercial Manufacturing [***], Genentech will [***] in the case of BioNTech Indications, or
[***] in the case of Reversion Products.’ 
  

	6.	 Costs. 

  

	 	a.	 The following provision is hereby added to the Agreement as Section 8.2.8: 

“RNA Manufacturing Project Costs. BioNTech shall be solely responsible for, and shall bear, all CMC Development Costs incurred by
or on behalf of BioNTech or Genentech in the performance of activities pursuant to a RNA Manufacturing Project. In the event that Genentech incurs CMC Development Costs in connection with an RNA Manufacturing Project, such costs shall be reported
to, and reimbursed by, BioNTech as part of the reconciliation process set forth in Sections 8.2.6 and 8.2.7. Genentech may offset the amounts of any invoices for such reconciled costs not paid in accordance with Section 8.2.7 from any payments
due to BioNTech pursuant to Sections 8.4.1 and 8.7. Notwithstanding the foregoing, for any portion of such CMC Development Costs that both (a) are incurred by or on behalf of Genentech in excess of [***] percent ([***]%) of the budget set forth

  
 3 

 
in the CMC Development Plan for activities allocated to Genentech pursuant to such RNA Manufacturing Project, and (b) have not been approved by BioNTech in advance, Genentech shall bear such
portion of the CMC Development Costs. For clarity, the costs of implementing any processes or developments made under an RNA Manufacturing Project into the Manufacturing Process for a Collaboration Product shall be Shared Development Costs.”

  

	 	b.	 The following provision is hereby added to the Agreement as Section 8.2.9: 

“Sequencing Manufacturing Project. Genentech shall be solely responsible for, and shall bear, all Development Costs incurred by it
and its Affiliates for the performance of the Sequencing Manufacturing Project by Genentech, its Affiliates or the External Sequencing Party.” 
  

	7.	 Intellectual Property. 

 

	 	a.	 The following is provision is hereby added to Section 10.2.1 as subsection (d): 

“[***]” 
  

	 	b.	 The following provision is hereby added to the Agreement as Section 10.2.5: 

“[***]” 
  

	8.	 Survival of Agreement Terms. All terms and conditions of the Agreement not modified by this Second
Amendment shall continue in full force and effect in accordance with their terms. All capitalized terms not otherwise defined herein shall have the same definition as in the Agreement. In the event of any conflict between the terms and conditions of
this Second Amendment and the Agreement, the terms and conditions set forth in this Second Amendment shall control with respect to the subject matter hereof. 

[Remainder of the page intentionally left blank; signature page follows.] 

  
 4 

 IN WITNESS WHEREOF, the Parties have each caused this Second Amendment to be executed by their duly
authorized representatives. 
  

									
	GENENTECH, INC.	 		 	 BIONTECH RNA

PHARMACEUTICALS GMBH

					
	By:	 	 /s/ Redacted
	 		 	By:	 	 /s/ Redacted

	Name:	 		 		 	Name:	 	
	Title:	 		 		 	Title:	 	
			
	F. HOFFMANN-LA ROCHE LTD	 		 	BIONTECH SE
					
	By:	 	 /s/ Redacted
	 		 	By:	 	 /s/ Redacted

	Name:	 		 		 	Name:	 	
	Title:	 		 		 	Title:	 	
			
	F. HOFFMANN-LA ROCHE LTD	 		 	
					
	By:	 	 /s/ Redacted
	 		 		 	
	Name:	 		 		 		 	
	Title:	 		 		 		 	

  
 5 

 Exhibit A 
  

									
	 Work Package
	  	 Objective
	  	 Key Deliverables
	  	 Target
Completion
Date
	  	 Target
Implementation
Date

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]EX-10.40

 Exhibit 10.40 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

			
		 	 Contract number (FI No):
 [***]

		
		 	 Contract number (FI No):
 [***]

		
		 	 Serapis No: [***]

 Personalised Immunotherapies (EGFF) 

Finance Contract 
 between the

 European Investment Bank 

and 
 BioNTech SE 

							
	 WHEREAS
	  	 	6	 
		
	 ARTICLE 1
	  	 	7	 
			
	 1.1
	 	INTERPRETATION	  	 	7	 
			
	 1.2
	 	DEFINITIONS	  	 	7	 
		
	 ARTICLE 2
	  	 	15	 
			
	 2.1
	 	AMOUNT OF CREDIT	  	 	15	 
			
	 2.2
	 	DISBURSEMENT PROCEDURE	  	 	15	 
			
	 2.2.1
	 	TRANCHES	  	 	15	 
	 2.2.2
	 	DISBURSEMENT OFFER	  	 	15	 
	 2.2.3
	 	DISBURSEMENT ACCEPTANCE	  	 	16	 
			
	 2.3
	 	DISBURSEMENT ACCOUNT	  	 	16	 
			
	 2.4
	 	CURRENCY OF DISBURSEMENT	  	 	16	 
			
	 2.5
	 	CONDITIONS OF DISBURSEMENT	  	 	16	 
			
	 2.5.1
	 	INITIAL DOCUMENTARY CONDITIONS PRECEDENT	  	 	16	 
	 2.5.2
	 	CREDIT B – FURTHER CONDITIONS PRECEDENT	  	 	16	 
	 2.5.3
	 	ALL TRANCHES - DOCUMENTARY CONDITIONS PRECEDENT	  	 	16	 
	 2.5.4
	 	ALL TRANCHES – OTHER CONDITIONS	  	 	17	 
			
	 2.6
	 	CANCELLATION	  	 	17	 
			
	 2.7
	 	FEE FOR CANCELLATION OF AN ACCEPTED TRANCHE	  	 	17	 
			
	 2.8
	 	CANCELLATION AFTER EXPIRY OF THE CREDIT	  	 	18	 
			
	 2.9
	 	STANDBY FEE	  	 	18	 
			
	 2.10
	 	SUMS DUE UNDER ARTICLE 2	  	 	18	 
		
	 ARTICLE 3
	  	 	18	 
			
	 3.1
	 	AMOUNT OF LOAN	  	 	18	 
			
	 3.2
	 	CURRENCY OF REPAYMENT, INTEREST AND OTHER CHARGES	  	 	18	 
		
	 ARTICLE 4
	  	 	18	 
			
	 4.1
	 	CASH INTEREST FIXED RATE	  	 	18	 
			
	 4.2
	 	DEFERRED INTEREST FIXED RATE	  	 	19	 
			
	 4.3
	 	PROFIT PARTICIPATION	  	 	19	 
			
	 4.4
	 	INTEREST ON OVERDUE SUMS	  	 	19	 
		
	 ARTICLE 5
	  	 	20	 
			
	 5.1
	 	NORMAL REPAYMENT	  	 	20	 
			
	 5.2
	 	VOLUNTARY PREPAYMENT	  	 	20	 
			
	 5.2.1
	 	PREPAYMENT OPTION	  	 	20	 
	 5.2.2
	 	PREPAYMENT FEE	  	 	20	 
	 5.2.3
	 	PREPAYMENT MECHANICS	  	 	20	 
			
	 5.3
	 	COMPULSORY PREPAYMENT	  	 	21	 
			
	 5.3.1
	 	COST REDUCTION	  	 	21	 
	 5.3.2
	 	CHANGE EVENTS	  	 	21	 
	 5.3.3
	 	ILLEGALITY	  	 	21	 
	 5.3.4
	 	DISPOSALS	  	 	21	 
	 5.3.5
	 	EXPIRY OF GUARANTEE AGREEMENT	  	 	22	 
	 5.3.6
	 	PARI PASSU TO NON-EIB FINANCING	  	 	22	 
	 5.3.7
	 	PREPAYMENT FEE	  	 	22	 
	 5.3.8
	 	PREPAYMENT MECHANICS	  	 	22	 

							
	 5.4
	 	GENERAL	  	 	22	 
		
	 ARTICLE 6
	  	 	22	 
			
	 6.1
	 	DAY COUNT CONVENTION	  	 	22	 
			
	 6.2
	 	TIME AND PLACE OF PAYMENT	  	 	23	 
			
	 6.3
	 	NO SET-OFF BY THE BORROWER	  	 	23	 
			
	 6.4
	 	DISRUPTION TO PAYMENT SYSTEMS	  	 	23	 
			
	 6.5
	 	APPLICATION OF SUMS RECEIVED	  	 	23	 
			
	 6.5.1
	 	GENERAL	  	 	23	 
	 6.5.2
	 	PARTIAL PAYMENTS	  	 	23	 
	 6.5.3
	 	ALLOCATION OF SUMS RELATED TO TRANCHES	  	 	24	 
		
	 ARTICLE 7
	  	 	24	 
		
	 ARTICLE 8
	  	 	24	 
			
	 8.1
	 	TAXES, DUTIES AND FEES	  	 	24	 
			
	 8.2
	 	OTHER CHARGES	  	 	24	 
			
	 8.3
	 	INCREASED COSTS, INDEMNITY AND SET-OFF	  	 	25	 
		
	 ARTICLE 9
	  	 	25	 
			
	 9.1
	 	RIGHT TO DEMAND REPAYMENT	  	 	25	 
			
	 9.2
	 	OTHER RIGHTS AT LAW	  	 	26	 
			
	 9.3
	 	PREPAYMENT FEE	  	 	27	 
			
	 9.4
	 	NON-WAIVER	  	 	27	 
		
	 ARTICLE 10
	  	 	27	 
			
	 10.1
	 	GOVERNING LAW	  	 	27	 
			
	 10.2
	 	JURISDICTION	  	 	27	 
			
	 10.3
	 	PLACE OF PERFORMANCE	  	 	27	 
			
	 10.4
	 	EVIDENCE OF SUMS DUE	  	 	27	 
			
	 10.5
	 	THIRD PARTY RIGHTS	  	 	27	 
			
	 10.6
	 	ENTIRE AGREEMENT	  	 	28	 
			
	 10.7
	 	INVALIDITY	  	 	28	 
			
	 10.8
	 	AMENDMENTS	  	 	28	 
			
	 10.9
	 	COUNTERPARTS	  	 	28	 
			
	 10.10
	 	ASSIGNMENT AND TRANSFER BY THE BANK	  	 	28	 
		
	 ARTICLE 11
	  	 	29	 
			
	 11.1
	 	NOTICES	  	 	29	 
			
	 11.1.1
	 	FORM OF NOTICE	  	 	29	 
	 11.1.2
	 	ADDRESSES	  	 	30	 
	 11.1.3
	 	DEMAND AFTER NOTICE TO REMEDY	  	 	30	 
			
	 11.2
	 	ENGLISH LANGUAGE	  	 	30	 
			
	 11.3
	 	CONCLUSION OF THIS CONTRACT (VERTRAGSSCHLUSS)	  	 	30	 
		
	 SCHEDULE A
	  	 	33	 
		
	 INVESTMENT SPECIFICATION AND REPORTING
	  	 	33	 
		
	 SCHEDULE B
	  	 	36	 

  

					
		  	Personalised Immunotherapies (EGFF).	  	3

					
		
	 DEFINITION OF EURIBOR
	  	 	36	 
		
	 SCHEDULE C
	  	 	37	 
		
	 FORM OF DISBURSEMENT OFFER/ACCEPTANCE
	  	 	37	 
		
	 SCHEDULE D
	  	 	39	 
		
	 FORM OF DRAWDOWN CERTIFICATE
	  	 	39	 
		
	 SCHEDULE E
	  	 	40	 
		
	 FORM OF COMPLIANCE CERTIFICATE
	  	 	40	 
		
	 SCHEDULE F
	  	 	41	 
		
	 PART A - INITIAL DOCUMENTARY CONDITIONS PRECEDENT AND CREDIT A CONDITIONS PRECEDENTS
	  	 	41	 
		
	 PART B – CREDIT B CONDITIONS PRECEDENT
	  	 	42	 
		
	 PART C – GUARANTOR CONDITIONS PRECEDENT
	  	 	42	 
		
	 SCHEDULE G
	  	 	44	 
		
	 REPRESENTATIONS AND WARRANTIES
	  	 	44	 
		
	 SCHEDULE H
	  	 	47	 
		
	 GENERAL UNDERTAKINGS
	  	 	47	 
		
	 SCHEDULE I
	  	 	56	 
		
	 INFORMATION AND VISITS
	  	 	56	 
		
	 SCHEDULE J
	  	 	61	 
		
	 EXISTING INDEBTEDNESS
	  	 	61	 
		
	 SCHEDULE K
	  	 	62	 
		
	 EXISTING SECURITY
	  	 	62	 

  

					
		  	Personalised Immunotherapies (EGFF).	  	4

 THIS CONTRACT IS MADE ON _12 DECEMBER 2019 BETWEEN: 

 

			
	 The European Investment Bank having its
	  	 (the “Bank”)

	 seat at 100 blvd Konrad Adenauer,
	  	
	 Luxembourg, L-2950 Luxembourg,
	  	
	 represented by Hristo Stoykov, Head of
	  	
	 Division and Stefan Becker, Senior Counsel
	  	
		
	and	  	
		
	 BioNTech SE a European public limited-
	  	 (the “Borrower”)

	 liability company (Europäische Gesellschaft)
	  	
	 incorporated in Germany, having its
	  	
	 registered office at An der Goldgrube 12, D-
	  	
	 55131 Mainz, Germany, registered with the
	  	
	 commercial register (Handelsregister) of the
	  	
	 local court (Amtsgericht) of Mainz under
	  	
	 HRB 48720, represented by Dr. Sierk
	  	
	 Poetting, CFO & COO (Vorstand)
	  	

  

					
		  	Personalised Immunotherapies (EGFF).	  	5

 WHEREAS: 
  

	(A)	 The Borrower has stated that it is implementing an investment programme relating to R&D investments for the
development of patient-tailored therapeutic vaccines for cancer in Germany as more particularly described in the technical description (the “Technical Description”) set out in Schedule A (Investment Specification and
Reporting) (the “Investment”). The total cost of the Investment, as estimated by the Bank, is EUR [***]. 

  

	(B)	 The Bank, considering that the financing of the Investment falls within the scope of its functions, agreed to
provide the Borrower with a credit (including a profit participation credit (partiarisches Darlehen)) in an amount of EUR 50,000,000 (fifty million euro) under this finance contract (the “Contract”) to partially finance the
Investment; provided that the amount of the loan hereunder shall not, in any case, exceed 50% (fifty per cent.) of the cost of the Investment. The Parties being aware of the differences between a profit participation credit (partiarisches
Darlehen) and a silent partnership (stille Gesellschaft), have consciously decided to enter into this Contract. 

  

	(C)	 This operation benefits from a guarantee from the European Union under the European Fund for Strategic
Investments (“EFSI”). 

  

	(D)	 The statute of the Bank provides that the Bank shall ensure that its funds are used as rationally as possible
in the interests of the European Union; and, accordingly, the terms and conditions of the Bank’s loan operations must be consistent with relevant policies of the European Union. 

 

	(E)	 The Bank considers that access to information plays an essential role in the reduction of environmental and
social risks, including human rights violations, linked to the projects it finances and has therefore established its transparency policy, the purpose of which is to enhance the accountability of the Bank’s group towards its stakeholders and
the citizens of the European Union in general. 

  

	(F)	 The processing of personal data shall be carried out by the Bank in accordance with applicable European Union
legislation on the protection of individuals with regard to the processing of personal data by the European Union institutions and bodies and on the free movement of such data. 

 

	(G)	 The Bank places great emphasis on integrity and good governance and has therefore established policies and
procedures to avoid misuse of its funds for purposes of tax fraud, tax evasion, money laundering and financing of terrorism, and with a view to protect against its operations financing artificial arrangements aimed at tax avoidance. Such policies
and procedures are designed to be in line with the principles and standards of applicable EU Law, and European Union or internationally agreed tax standards on transparency and exchange of information. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	6

 It is hereby agreed as follows: 

ARTICLE 1 

Interpretation and definitions 
  

	1.1	 Interpretation 

In this Contract: 
  

	 	(a)	 references to Articles, Recitals, Schedules and (Sub-)Paragraphs are,
save if explicitly stipulated otherwise, references respectively to articles of, and recitals, schedules and (sub-)paragraphs of schedules to, this Contract. All Recitals and Schedules form part of this
Contract; 

  

	 	(b)	 references to “law” or “laws” mean (i) any applicable law and any applicable treaty,
constitution, statute, legislation, decree, normative act, rule, regulation, judgement, order, writ, injunction, determination, award or other legislative or administrative measure or judicial or arbitral decision in any jurisdiction which is
binding or applicable case law, and (ii) EU Law; 

  

	 	(c)	 references to applicable law, applicable laws or applicable jurisdiction means (i) a law or jurisdiction
applicable to the Borrower or any other Obligor (as the context requires), its respective rights and/or obligations (in each case arising out of or in connection with the Finance Documents), its capacity and/or assets and/or the Investment; and/or,
as applicable, (ii) a law or jurisdiction (including in each case the Bank’s Statute) applicable to the Bank, its rights, obligations, capacity and/or assets; 

 

	 	(d)	 references to a provision of law are references to that provision as amended or re-enacted;

  

	 	(e)	 references to any Finance Document or other agreement or instrument are references to that Finance Document or
other agreement or instrument as amended, novated, supplemented, extended or restated; 

  

	 	(f)	 words and expressions in plural shall include singular and vice versa; 

 

	 	(g)	 “promptly” is to be construed as unverzüglich (without undue delay) within the meaning of
Section 121 para. 11 of the BGB; and 

  

	 	(h)	 a Default (other than an Event of Default) is “continuing” if it has not been remedied or waived and
an Event of Default is “continuing” if it has not been waived. 

 This Contract is made in the English language.
For the avoidance of doubt, the English language version of this Contract shall prevail over any translation of this Contract. However, where a German translation of a word or phrase appears in the text of this Contract, the German translation of
such word or phrase shall prevail. 
  

	1.2	 Definitions 

In this Contract: 

“Accepted Tranche” means a Tranche in respect of a Disbursement Offer which has been duly accepted by the Borrower in
accordance with its terms on or before the Disbursement Acceptance Deadline. 
 “acting in concert” means acting together
pursuant to an agreement or understanding (whether formal or informal). 
 “AktG” means the German stock corporation act
(Aktiengesetz). 
 “Approved Financial Statements” has the meaning given to that term in Paragraph 2.(a)(i) of
Schedule I (Information and Visits). 
 “Authorisation” means an authorisation, permit, consent, approval,
resolution, licence, exemption, filing, notarisation or registration. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	7

 “Authorised Signatory” means a person authorised to sign individually or
jointly (as the case may be) Disbursement Acceptances on behalf of the Borrower and named in the most recent List of Authorised Signatories and Accounts received by the Bank prior to the receipt of the relevant Disbursement Acceptance. 

“BGB” means the German Civil Code (Bürgerliches Gesetzbuch). 

“Business Day” means a day (other than a Saturday or Sunday) on which the Bank and commercial banks are open for general
business in Luxembourg and Mainz, Germany. 
 “Cancellation Fee” has the meaning given to such term in Article 1.2
(Definitions) of the Finance Fee Letter. 
 “Cash Interest Fixed Rate” means (i) in relation to Credit A a fixed
rate of 1% (100 basis points) per annum and (ii) in relation to Credit B a fixed rate of 2% (200 basis points) per annum. 
 “Change-of-Control Event” means: 
  

	 	(a)	 any person or group of persons acting in concert gains Control of the Borrower or of any entity directly or
indirectly Controlling the Borrower; or 

  

	 	(b)	 the Borrower ceases to Control any Guarantor; or 

 

	 	(c)	 a Delisting of the Borrower. 

“Change-of-Law Event” means the enactment,
promulgation, execution or ratification of or any change in or amendment to any law, rule or regulation (or in the application or official interpretation of any law, rule or regulation) that occurs after the date of this Contract and which, in the
opinion of the Bank, would materially impair an Obligor’s ability to perform its obligations under the Finance Documents. 

“Compliance Certificate” means a certificate substantially in the form set out in Schedule E (Form of Compliance
Certificate). 
 “Contract Number” shall mean each Bank generated number identifying this Contract and indicated on the
cover page of this Contract after the letters “FI No”. 
 “Control” means (i) owning (directly or indirectly)
more than 50% (fifty per cent) of the shares in an entity, (ii) the power to cast, or to control the casting of, more than 50% (fifty per cent) of the maximum number of votes that might be cast at a shareholder or general meeting of an entity,
(iii) the power to appoint or remove all, or the majority, of the directors of an entity, and/or (iv) the power to direct the management and policies of an entity, whether through the ownership of voting capital, by contract or otherwise,
and “Controlling” and “Controlled” has the corresponding meaning. 
 “Credit” has the
meaning given to it in Article 2.1 (Amount of Credit). 
 “Credit A” has the meaning given to it in Article 2.1(a)
(Amount of Credit). 
 “Credit A Milestone Events” has the meaning given to such term in Part A (Initial
Documentary Conditions Precedent and Credit A Conditions Precedents) of Schedule F. 
 “Credit B” has the meaning given
to it in Article 2.1(b) (Amount of Credit). 
 “Credit B Milestone Events” has the meaning given to such term in Part
B (Credit B – Conditions Precedent) of Schedule F. 
 “Default” means an Event of Default or any event or
circumstance specified in Article 9 (Events of Default) which would (with the expiry of a grace period, the giving of notice, the making of any determination under this Contract or any combination of any of the foregoing) be an Event of
Default. 
 “Deferred Interest Fixed Rate” means in relation to Credit A a fixed rate of 5% (500 basis points) per annum.

 “Delisting” means voluntary or involuntary removal of listed shares from a regulated market or revocation of admission to
trading of shares on a regulated market. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	8

 “Disbursement Acceptance” means a copy of the Disbursement Offer duly
countersigned by the Borrower. 
 “Disbursement Acceptance Deadline” means the date and time of expiry of a Disbursement
Offer as specified therein. 
 “Disbursement Account” means, in respect of each Tranche, the bank account set out in the
most recent List of Authorised Signatories and Accounts. 
 “Disbursement Date” means the date on which disbursement of a
Tranche is made by the Bank. 
 “Disbursement Offer” means a letter substantially in the form set out in Schedule C (Form
of Disbursement Offer/Acceptance). 
 “Dispute” has the meaning given to it in Article 10.2 (Jurisdiction). 

“Disruption Event” means either or both of: 
  

	 	(a)	 a material disruption to those payment or communications systems or to those financial markets which are, in
each case, required to operate in order for payments to be made in connection with this Contract; or 

  

	 	(b)	 the occurrence of any other event which results in a disruption (of a technical or systems-related nature) to
the treasury or payments operations of either the Bank or the Borrower, preventing that party from: 

  

	 	(i)	 performing its payment obligations under this Contract; or 

 

	 	(ii)	 communicating with other parties in accordance with the terms of this Contract, 

and which disruption (in either such case as per Paragraph (a) or (b) above) is not caused by, and is beyond the control of, the party
whose operations are disrupted. 
 “Drug Product Revenues” means the amount of the consolidated revenues resulting from drug
product sales (including royalties) of the Group Companies, calculated on the basis of the Approved Financial Statements for the respective financial year, excluding milestone and upfront payments as well as revenues associated with peptides,
diagnostics and contract development and manufacturing businesses of JPT Peptide Technologies GmbH, BioNTech Diagnostics GmbH and BioNTech Innovative Manufacturing Services GmbH. In the case that Intellectual Property Rights related to drug assets
that are either fully or partly-owned by the Borrower or any other Group Company as at the date of this Contract or in the future are out-licensed or partnered in a co-development deal, the total drug revenues
generated on the market shall be considered for the calculation of Drug Product Revenues (rather than the percentage of revenues due to the Borrower or the respective other Group Company). 

“EBITDA” means, in respect of any Relevant Period, the consolidated operating profit of the Group before taxation (excluding
the results from discontinued operations): 
  

	 	(a)	 after deducting own work capitalised; 

 

	 	(b)	 before deducting any interest, commission, fees, discounts, prepayment fees, premiums or charges and other
finance payments whether paid, payable or capitalised by any Group Company (calculated on a consolidated basis) in respect of that Relevant Period; 

  

	 	(c)	 not including any accrued interest owing to any Group Company; 

 

	 	(d)	 after adding back any amount attributable to the amortisation or depreciation of assets of members of the
Group; 

  

	 	(e)	 before taking into account any Exceptional Items; 

 

	 	(f)	 after deducting the amount of any profit (or adding back the amount of any loss) of any Group Company which is
attributable to minority interests; 

  

	 	(g)	 plus or minus the Group’s share of the profits or losses (after finance costs and tax) of entities which
are not Group Companies; 

  

					
		  	Personalised Immunotherapies (EGFF).	  	9

	 	(h)	 before taking into account any unrealised gains or losses on any financial instrument (other than any
derivative instrument which is accounted for on a hedge accounting basis); and 

  

	 	(i)	 before taking into account any gain arising from an upward revaluation of any other asset,

 in each case, to the extent added, deducted or taken into account, as the case may be, for the purposes of determining
operating profits of the Group before taxation. 
 “EIB Fee Letter” means the letter from the Bank to the Borrower dated 31
October 2018. 
 “EFSI” has the meaning given in Recital (C). 

“EFSI Regulation” means the Regulation 2015/1017 of the European Parliament and of the Council of 25 June 2015 on the European
Fund for Strategic Investments, as amended, supplemented or restated. 
 “Environment” means the following, in so far as
they affect human health or social well-being: 
  

	 	(a)	 fauna and flora; 

  

	 	(b)	 soil, water, air, climate and the landscape; and 

 

	 	(c)	 cultural heritage and the built environment, 

and includes, without limitation, occupational and community health and safety. 

“Environmental Approval” means any Authorisation required by Environmental Law. 

“Environmental Claim” means any claim, proceeding, formal notice or investigation by any person in respect of any
Environmental Law. 
 “Environmental Law” means EU Law including principles and standards, and national laws and
regulations, of which a principal objective is the preservation, protection or improvement of the Environment. 
 “Expert
Determination” has the meaning given to it in Article 4.3(d) (Profit Participation). 
 “Existing
Indebtedness” means any Indebtedness of members of the Group arising under any arrangement listed in Schedule J (Existing Indebtedness). 

“Existing Security” means any Security granted by members of the Group which are listed in Schedule K (Existing
Security). 
 “EU Directives” means the directives of the European Union. 

“EU Law” means the acquis communautaire of the European Union as expressed through the Treaties of the European Union, the
regulations, the EU Directives, delegated acts, implementing acts, and the case law of the Court of Justice of the European Union. 

“EUR” or “euro” means the lawful currency of the Member States of the European Union which adopt or have
adopted it as their currency in accordance with the relevant provisions of the Treaty on European Union and the Treaty on the Functioning of the European Union or their succeeding treaties. 

“EURIBOR” has the meaning given to it in Schedule B (Definition of EURIBOR). 

“Event of Default” means any of the circumstances, events or occurrences specified in Article 9 (Events of Default).

 “Exceptional Items” means any material items of an unusual or non-recurring
nature which represent gains or losses including those arising on: 
  

	 	(a)	 the restructuring of the activities of an entity and reversals of any provisions for the cost of restructuring;

  

	 	(b)	 disposals, revaluations, write downs or impairment of non-current
assets or any reversal of any write down or impairment; 

  

					
		  	Personalised Immunotherapies (EGFF).	  	10

	 	(c)	 disposals of assets associated with discontinued operations; and 

 

	 	(d)	 any other examples of “exceptional items” (as such term has the meaning attributed to it in IFRS).

 “Fee Letters” means the EIB Finance Letter and the Finance Fee Letter. 

“Finance Fee Letter” means the Luxembourg law governed finance fee letter from the Bank to the Borrower dated on or about the
date hereof. 
 “Final Availability Date” means the day falling [***] months after the date of this Contract. 

“Finance Documents” means this Contract, any Guarantee Agreement, the Security Documents, the Fee Letters and any other
document designated a “Finance Document” by the Borrower and the Bank. 
 “Finance Lease” means any lease or hire
purchase contract which would, in accordance with IFRS in force prior to 1 January 2019, be treated as a finance or capital lease; it is understood between the parties to this Contract that the definition of “Finance Lease” does not
include operational lease. 
 “GAAP” means generally accepted accounting principles (Grundsätze
ordnungsgemäßer Buchführung) in Germany, including IFRS. 
 “Germany” means the Federal
Republic of Germany. 
 “Group” means the Group Companies, taken together as a whole. 

“Group Company” means the Borrower and its Subsidiaries. 

“Guarantee Agreement” means a guarantee and indemnity agreement in form and substance satisfactory to the Bank (to be) entered
into by a Guarantor as guarantor and the Bank as beneficiary. 
 “Guarantor” means BioNTech RNA Pharmaceuticals GmbH and
each Material Subsidiary which enters into a Guarantee Agreement in accordance with Sub-Paragraph (b) of Paragraph 16 (Guarantees) of Schedule H (General Undertakings). 

“IFRS” means international accounting standards within the meaning of IAS Regulation 1606/2002 to the extent applicable to the
relevant financial statements. 
 “Illegal Activities” means any of the following illegal activities or activities carried
out for illegal purposes: tax evasion, tax fraud, fraud, corruption, coercion, collusion, obstruction, money laundering, financing of terrorism or any illegal activity that may affect the financial interests of the EU, according to applicable laws.

 “Indebtedness” means any: 
  

	 	(a)	 obligations for borrowed money; 

 

	 	(b)	 indebtedness under any acceptance credit; 

 

	 	(c)	 indebtedness under any bond, debenture, note or similar instrument; 

 

	 	(d)	 instrument under any bill of exchange; 

 

	 	(e)	 indebtedness in respect of any interest rate or currency swap or forward currency sale or purchase or other
form of interest or currency hedging transaction (including without limit caps, collars and floors); 

  

	 	(f)	 indebtedness under any Finance Lease; 

 

	 	(g)	 indebtedness (actual or contingent) under any guarantee, bond security, indemnity or other agreement;

  

	 	(h)	 indebtedness (actual or contingent) under any instrument entered into for the purpose of raising finance;

  

	 	(i)	 indebtedness in respect of a liability to reimburse a purchaser of any receivables sold or discounted in the
event that any amount of those receivables is not paid; 

  

	 	(j)	 indebtedness arising under a securitisation; or 

  

					
		  	Personalised Immunotherapies (EGFF).	  	11

	 	(k)	 other transaction which has the commercial effect of borrowing. 

“Independent Expert” means an investment bank or consultancy firm of international standing and repute, appointed by the
Borrower and accepted by the Bank. 
 “Initial Ownership Stake” has the meaning given to that term in Paragraph 13 (b)(i) of
Schedule H (General Undertakings). 
 “InsO” means the German Insolvency Code (Insolvenzordnung). 

“Intellectual Property Rights” means intellectual property rights (gewerbliche Schutzrechte;
Immaterialgüterrechte) of every designation (including, without limitation, patents, utility patents, copyrights, design rights, trademarks, software, service marks and know how) whether capable of registration or not. 

“Investment” has the meaning given to that term in Recital (A). 

“Land Charge” means the first ranking land charge without certificate (Buchgrundschuld) in the amount of EUR 50,000,000
(plus [***]) created under the Land Charge Creation Deed with which the Borrower will encumber its Property and certain of its assets falling within the statutory scope of the Land Charge (Grundschuldhaftungsverband) in favour of the Bank.

 “Land Charge Creation Deed” means any document by means of which the Land Charge is created and which includes, inter
alia, an abstract acknowledgement of debt of the Borrower in the amount of the Land Charge (in each case subject to the submission to the immediate enforcement (sofortige Zwangsvollstreckungsunterwerfung) in personam and in rem
for the full Land Charge amount), the Borrower’s approval for registration (Eintragungsbewilligung) of the Land Charge in the land register, regardless of whether such document will be officially certified (öffentlich
beglaubigt) or notarially recorded (notariell beurkundet). 
 “Lead Organisation” means the European Union, the
United Nations and international standard setting organisations including the International Monetary Fund, the Financial Stability Board, the Financial Action Task Force, the Organisation for Economic Cooperation and Development and the Global Forum
on Transparency and Exchange of Information for Tax Purposes and any successor organisations. 
 “List of Authorised Signatories and
Accounts” means a list (signed by Authorised Signatories), in form and substance satisfactory to the Bank, setting out: (i) the Authorised Signatories, accompanied by evidence of signing authority of the persons named on the list and
specifying if they have individual or joint signing authority, (ii) the specimen signatures of such persons, and (iii) the bank account(s) to which disbursements may be made under this Contract (specified by IBAN code if the country is
included in the IBAN Registry published by SWIFT, or in the appropriate account format in line with the local banking practice), BIC/SWIFT code of the bank and the name of the bank account(s) beneficiary. 

“Loan” means the aggregate of the amounts disbursed from time to time by the Bank under this Contract. 

“Loan Outstanding” means the aggregate of the amounts disbursed from time to time by the Bank under this Contract that remains
outstanding. 
 “Material Adverse Change” means, any event or change of condition, which, in the reasonable opinion of the
Bank has a material adverse effect on: 
  

	 	(a)	 the ability of any Obligor to perform its respective obligations under the Finance Documents;

  

	 	(b)	 the business, operations, property or condition (financial or otherwise) of any Obligor or the Group as a
whole; or 

  

	 	(c)	 the legality, validity or enforceability of, or the effectiveness or ranking of, or the value of any Security
granted to the Bank, or the rights or remedies of the Bank under the Finance Documents. 

 “Material
Subsidiary” means BioNTech RNA Pharmaceuticals GmbH and any Subsidiary from time to time, whose gross revenues, total assets or EBITDA represents more than 5% of (i) the consolidated gross revenues of the Group or, (ii) the Total
Assets, or, (iii) as the case may be, the consolidated EBITDA of the Group, as calculated based on the then latest consolidated audited accounts of the Group. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	12

 “Maturity Date” means, for each Tranche, the last Repayment Date of that
Tranche as specified in the relevant Disbursement Offer, being the date falling 6 (six) years from the respective Disbursement Date of the relevant Tranche. 

“Milestone Events” means collectively the Credit A Milestone Events and the Credit B Milestone Events. 

“Non-EIB Financing” includes any loan (save for the Loan and any other direct loans
from the Bank to the Borrower (or any other Group Company) or a Guarantor), credit bond or other form of financial indebtedness or any obligation for the payment or repayment of money originally granted to the Borrower (or any other Group Company)
or a Guarantor) for a term of more than 3 (three) years. 
 “Obligor” means the Borrower and each Guarantor. 

“Payment Date” means the quarterly dates specified in the Disbursement Offer until and including the Maturity Date, save that,
in case any such date is not a Relevant Business Day, it means the following Relevant Business Day, without adjustment to the interest due under Article 4 (Interest), except for those cases where a payment is made as a single instalment in
accordance with Article 5.1 (Normal Repayment), and to the final interest payment only, when it shall mean the preceding Relevant Business Day, with adjustment to the interest due under Article 4 (Interest). 

“Permitted Disposal” means each disposal permitted in accordance with Paragraph 7(b) (Disposal of assets) of Schedule H
(General Undertakings). 
 “Permitted Guarantees” means each and every guarantee permitted in accordance with
Paragraph 16 (Guarantees) of Schedule H (General Undertakings). 
 “Permitted Hedging” has the meaning given
to such term in Paragraph 17 (Hedging) of Schedule H (General Undertakings). 
 “Permitted Indebtedness” means
Indebtedness of the Borrower and/or any Group Company which is permitted in accordance with Paragraph 15 (Indebtedness) of Schedule H (General Undertakings). 

“Permitted Security” means Security of the Borrower and/or any Group Company which is permitted in accordance with Sub-Paragraph (c) Paragraph 23 (Negative pledge) of Schedule H (General Undertakings). 

“Prepayment Amount” means the amount of a Tranche to be prepaid by the Borrower in accordance with Articles 5.2 (Voluntary
prepayment), 5.3 (Compulsory prepayment) or 9.1 (Right to demand repayment). 
 “Prepayment Date” means
the date on which the Borrower proposes or is requested by the Bank, as applicable, to effect prepayment of a Prepayment Amount. 

“Prepayment Event” means any of the events described in Article 5.3 (Compulsory Prepayment). 

“Prepayment Fee” means, in relation to a Prepayment Amount in respect of a Tranche, a fee as follows: 

 

	 	(a)	 a fee of 4% (400 basis points) of the Prepayment Amount if the Prepayment Date is after the relevant
Disbursement Date but before or on the first anniversary of such Disbursement Date; 

  

	 	(b)	 a fee of 3% (300 basis points) of the Prepayment Amount if the Prepayment Date is after the first anniversary
of the relevant Disbursement Date but before or on the second anniversary of such Disbursement Date; 

  

	 	(c)	 a fee of 2% (200 basis points) of the Prepayment Amount if the Prepayment Date is after the second anniversary
of the relevant Disbursement Date but before or on the third anniversary of such Disbursement Date; 

  

					
		  	Personalised Immunotherapies (EGFF).	  	13

	 	(d)	 a fee of 1% (100 basis points) of the Prepayment Amount if the Prepayment Date is after the third anniversary
of the relevant Disbursement Date but before or on the fourth anniversary of such Disbursement Date; or 

  

	 	(e)	 a fee of 0.5% (50 basis points) of the Prepayment Amount if the Prepayment Date is after the fourth anniversary
of the relevant Disbursement Date but before the Maturity Date, 

 with such fee being payable on the applicable Prepayment
Date. 
 “Prepayment Notice” means a written notice from the Bank to the Borrower in accordance with Article 5.2.3
(Prepayment mechanics). 
 “Prepayment Request” means a written request from the Borrower to the Bank to prepay all
or part of the Loan Outstanding, in accordance with Article 5.2.1 (Prepayment option). 
 “Profit Participation Cap”
means, at any time, an amount of EUR 15,000,000 (fifteen million euro) or any other amount agreed between the Bank and the Borrower in writing. 

“Profit Participation Payments” has the meaning given to it in Article 4.3 (Profit Participation). 

“Property” means the property of BioNTech Real Estate GmbH & Co. KG at Hechtsheimer Straße, Mainz-Weisenau,
Rheinland-Pfalz, Germany, consisting of building and land, registered with the land register (Grundbuch) of the local court (Amtsgericht) of Mainz, folio 6393, district of Weisenau, plot (Flur) 2, parcels (Flurstück) 35/67. 

“Relevant Business Day” means a day on which the Trans-European Automated Real-time Gross Settlement Express Transfer payment
system which utilises a single shared platform and which was launched on 19 November 2007 (TARGET2) is open for the settlement of payments in EUR. 

“Relevant Period” means each period of 12 (twelve) months ending on or about the last day of the financial year. 

“Repayment Date” shall mean the sole Payment Date specified in the Disbursement Offer for the repayment of a Tranche in
accordance with Article 5.1 (Normal repayment). 
 “Repeating Representations” means each of the representations set
out in Schedule G (Representations and Warranties) other than those Paragraphs thereof which are identified with the words “(Non-repeating)” at the end of the Paragraphs. 

“Security” means any mortgage, land charge (Grundschuld), pledge, lien, charge, assignment, security transfer
(Sicherungsübereignung), retention of title arrangements, hypothecation, or other security interest securing any obligation of any person or any other agreement or arrangement having a similar effect. 

“Security Purpose Agreement” means the security purpose agreement (Sicherungszweckvereinbarung) to be entered into by
the Borrower as security grantor and the Bank as beneficiary in relation to the Land Charge. 
 “Security Documents” means
the Land Charge Creation Deed, the Security Purpose Agreement, each Guarantee Agreement and any other document entered into by any person creating or expressed to create any Security over all or any part of its assets in respect of the obligations
of any of the Obligors under any of the Finance Documents. 
 “Semi-Annual Date” means each of 30 June and 31 December. 

“Standby Fee” has the meaning given to such term in Article 2. (Standby fee) of the Finance Fee Letter. 

“Subsidiary” means a subsidiary within the meaning of Sections 15 to 17 AktG and an entity of which the Borrower has direct or
indirect Control. 
 “Tax” means any tax, levy, impost, duty or other charge or withholding of a similar nature (including
any penalty or interest payable in connection with any failure to pay or any delay in paying any of the same). 
 “Technical
Description” has the meaning given to it in Recital (A). 

  

					
		  	Personalised Immunotherapies (EGFF).	  	14

 “Total Assets” means the total consolidated assets of the Group, as shown
in the Borrower’s latest consolidated financial statements, as at the end of any Relevant Period. 
 “Tranche” means
each disbursement made or to be made under this Contract. In the event that no Disbursement Acceptance has been received, Tranche shall mean a Tranche as offered under Article 2.2.2 (Disbursement Offer). 

“Voluntary Non EIB Prepayment” means a voluntary prepayment by any Group Company or any Guarantor (for the avoidance of doubt,
prepayment shall include a repurchase, redemption or cancellation where applicable) of a part or the whole of any Non-EIB Financing where: 

 

	 	(a)	 such prepayment is not made within a revolving credit facility (save for the cancellation of a revolving credit
facility); or 

  

	 	(b)	 such prepayment is not made out of the proceeds of a loan or other indebtedness having a term at least equal to
the unexpired term of the Non-EIB Financing prepaid. 

 ARTICLE 2

 Credit and Disbursements 
  

	2.1	 Amount of Credit 

By this Contract, the Bank establishes in favour of the Borrower, and the Borrower accepts, a credit (including a profit participation credit
(partiarisches Darlehen)) in an aggregate amount of EUR 50,000,000 (fifty million euro) for the financing of the Investment (the “Credit”), consisting of: 

 

	 	(a)	 a term loan in an amount of EUR 25,000,000 (twenty five million euro) (“Credit
A”); and 

  

	 	(b)	 a term loan in an amount of EUR 25,000,000 (twenty five million euro) (“Credit B”).

  

	2.2	 Disbursement procedure 

 

	2.2.1	 Tranches 

The Bank shall disburse the Credit in Euros in up to five Tranches. Credit A can only be drawn in full, in an amount of EUR 25,000,000 (twenty
five million euro). The amount of each Tranche under Credit B, shall be in a minimum amount of EUR 5,000,000 (five million euro) or (if less) the entire undrawn balance of the Credit B. 

 

	2.2.2	 Disbursement Offer 

Upon request by the Borrower and subject to Article 2.5 (Conditions of Disbursement), provided that no event mentioned in Sub-Paragraph
(b) of Article 2.6 (Cancellation) has occurred and is continuing, the Bank shall send to the Borrower a Disbursement Offer for the disbursement of a Tranche. The latest time for receipt by the Borrower of a Disbursement Offer is [***] days
before the Final Availability Date. The Disbursement Offer shall specify: 
  

	 	(a)	 the amount of the Tranche; 

 

	 	(b)	 the Disbursement Date, which shall be a Relevant Business Day, falling at least [***] days after the date of
the Disbursement Offer and on or before the Final Availability Date; 

  

	 	(c)	 the interest rate basis of the Tranche, namely: 

 

	 	(i)	 the Cash Interest Fixed Rate applicable to such Tranche; 

 

	 	(ii)	 if relevant, the Deferred Interest Fixed Rate; and 

 

	 	(iii)	 the Payment Dates; 

  

	 	(d)	 the terms and frequency for repayment of principal (bullet); 

  

					
		  	Personalised Immunotherapies (EGFF).	  	15

	 	(e)	 the Maturity Date; and 

 

	 	(f)	 the Disbursement Acceptance Deadline. 

 

	2.2.3	 Disbursement Acceptance 

 

	 	(a)	 The Borrower may accept a Disbursement Offer by delivering a Disbursement Acceptance to the Bank no later than
the Disbursement Acceptance Deadline. The Disbursement Acceptance shall be signed by an Authorised Signatory with individual representation right or 2 (two) or more Authorised Signatories with joint representation rights and shall specify the
Disbursement Account to which disbursement of the Tranche should be made in accordance with Article 2.3 (Disbursement Account). 

  

	 	(b)	 If a Disbursement Offer is duly accepted by the Borrower in accordance with its terms on or before the
Disbursement Acceptance Deadline, and provided the conditions in Article 2.5.4 (All Tranches – Other Conditions) are met, the Bank shall make the Accepted Tranche available to the Borrower in accordance with the relevant Disbursement
Offer and subject to the terms and conditions of this Contract. 

  

	 	(c)	 The Borrower shall be deemed to have refused any Disbursement Offer which has not been duly accepted in
accordance with its terms on or before the Disbursement Acceptance Deadline, in which case the Tranche shall not be made available to the Borrower by the Bank, and the Credit shall not be affected. 

 

	2.3	 Disbursement Account 

 

	 	(a)	 Disbursement shall be made to the Disbursement Account specified in the relevant Disbursement Acceptance,
provided that such Disbursement Account is acceptable to the Bank in accordance with Article 6.2(d) (Time and place of payment). 

  

	 	(b)	 Only one Disbursement Account may be specified for each Tranche. 

 

	2.4	 Currency of disbursement 

The Bank shall disburse each Tranche in EUR. 
  

	2.5	 Conditions of Disbursement 

 

	2.5.1	 Initial Documentary Conditions Precedent 

Without prejudice to Article 2.5.2 below, no Disbursement Offer will be provided by the Bank under this Contract unless the Bank has received
all of the documents and other evidence listed in Schedule F, Part A (Initial Documentary Conditions Precedent and Credit A Conditions Precedents) in agreed form or otherwise in form and substance satisfactory to the Bank, including the
Credit A Milestone Events. 
  

	2.5.2	 Credit B – Further Conditions Precedent 

No Disbursement Offer will be provided by the Bank under this Contract in relation to Credit B unless the Bank has received all of the
additional documents and other evidence listed in Schedule F, Part B (Credit B – Conditions Precedent) in agreed form or otherwise in form and substance satisfactory to the Bank, including the Credit B Milestone Events. 

 

	2.5.3	 All Tranches - Documentary Conditions Precedent 

No Disbursement Offer, including the first Disbursement Offer, will be provided by the Bank under this Contract unless the Bank has confirmed
that it has received, in form and substance satisfactory to it: 
  

	 	(a)	 a certificate from the Borrower in the form of Schedule D (Form of Drawdown Certificate), signed by an
Authorised Signatory of the Borrower and dated no earlier than the date falling 14 (fourteen) days before the respective Disbursement Date; and 

  

					
		  	Personalised Immunotherapies (EGFF).	  	16

	 	(b)	 a certificate (signed by one or more Authorised Signatories of the Borrower as appropriate) from the Borrower
which confirms that the Borrower has sufficient resources to pay its debts as they fall due for at least 6 (six) months from the Disbursement Date not taking into account the disbursement of the proposed Tranche with a current extract from the
commercial register (Handelsregisterauszug) of the Borrower and an up-to-date search on www.insolvenzbekanntmachungen.de in relation to the Borrower attached.

  

	2.5.4	 All Tranches – Other Conditions 

The Bank will only be obliged to make any Accepted Tranche available to the Borrower if on the Disbursement Date for the proposed Tranche: 

 

	 	(a)	 the Repeating Representations made by the Borrower (in respect of itself and, where applicable, the other
Obligors) are correct in all respects; 

  

	 	(b)	 no event or circumstance has occurred and is continuing which constitutes: 

 

	 	(i)	 or would with the expiry of a grace period and/or the giving of notice under this Contract constitute a
Prepayment Event other than pursuant to Article 5.3.1 (Cost Reduction); or 

  

	 	(ii)	 a Default or an Event of Default, 

or would, in each case, result from the disbursement of the proposed Tranche; and 

 

	 	(c)	 the Borrower complies with all preceding and already achieved Milestone Events. 

 

	2.6	 Cancellation 

 

	 	(a)	 The Borrower may send a written notice to the Bank requesting the cancellation of the undisbursed portion of
the Credit. The written notice: 

  

	 	(i)	 must specify whether the Borrower would like to cancel the undisbursed portion of the Credit in whole or in
part and, if in part, the amount of the Credit the Borrower would like to cancel; and 

  

	 	(ii)	 must not relate to an Accepted Tranche which has a Disbursement Date falling within [***] Business Days of the
date of the written notice. 

 Upon receipt of such written notice, the Bank shall cancel the requested undisbursed
portion of the Credit with immediate effect. 
  

	 	(b)	 At any time upon the occurrence of the following events, the Bank may notify the Borrower in writing that the
undisbursed portion of the Credit shall be cancelled in whole or in part: 

  

	 	(i)	 a Prepayment Event, which for the avoidance of doubt and only in case of event pursuant to Article 5.3.1
(Cost Reduction), by an amount equal to the amount by which it is entitled to cancel the Credit; 

  

	 	(ii)	 an Event of Default; or 

 

	 	(iii)	 an event or circumstance which would with the passage of time or giving of notice under this Contract
constitute a Prepayment Event other than pursuant to Article 5.3.1 (Cost Reduction) or an Event of Default. 

 On
the date of such written notification the relevant undisbursed portion of the Credit shall be cancelled with immediate effect. 
  

	2.7	 Fee for cancellation of an Accepted Tranche 

 

	 	(a)	 If pursuant to Sub-Paragraph (a) of Article 2.6
(Cancellation) the Borrower cancels an Accepted Tranche, the Borrower shall pay to the Bank the Cancellation Fee in accordance with the terms of the Finance Fee Letter. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	17

	 	(b)	 If pursuant to Sub-Paragraph (b) of Article 2.6
(Cancellation) the Bank cancels all or part of an Accepted Tranche, the Borrower shall pay to the Bank the Cancellation Fee in accordance with the terms of the Finance Fee Letter. 

 

	 	(c)	 If an Accepted Tranche is not disbursed on the Disbursement Date because the conditions precedent set out in
Article 2.5.4 (All Tranches – Other Conditions) are not satisfied on such date, such Tranche shall be cancelled and the Borrower shall pay to the Bank the relevant Cancellation Fee in accordance with the terms of the Finance Fee Letter.

  

	2.8	 Cancellation after expiry of the Credit 

On the day following the Final Availability Date, and unless otherwise specifically agreed to in writing by the Bank, any part of the Credit in
respect of which no Disbursement Acceptance has been received in accordance with Article 2.2.3 (Disbursement Acceptance) shall be automatically cancelled, without any notice being served by the Bank to the Borrower. 

 

	2.9	 Standby fee 

 

	 	(a)	 The Borrower shall pay to the Bank the Standby Fee in accordance with the terms of the Finance Fee Letter.

  

	 	(b)	 For the avoidance of doubt, the Standby Fee payable under this Article 2.9 (Standby fee) is independent
of any other fees stipulated in this Contract. 

  

	2.10	 Sums due under Article 2 

Sums due under this Article 2 shall be payable in EUR. Sums due under this Article 2 shall be payable within [***] days of the Borrower’s
receipt of the Bank’s demand or within any longer period specified in the Bank’s demand. 
 ARTICLE 3 

The Loan 
  

	3.1	 Amount of Loan 

The Loan shall comprise the aggregate amount of Tranches disbursed by the Bank under the Credit. 

 

	3.2	 Currency of repayment, interest and other charges 

 

	 	(a)	 Interest, Participation Payments, repayments and other charges payable in respect of each Tranche shall be made
by the Borrower in EUR. 

  

	 	(b)	 Any other payment shall be made in the currency specified by the Bank having regard to the currency of the
expenditure to be reimbursed by means of that payment. 

 ARTICLE 4 

Interest 
  

	4.1	 Cash Interest Fixed Rate 

The Borrower shall pay interest on the outstanding balance of each Tranche under Credit A and Credit B at the respective Cash Interest Fixed
Rate quarterly in arrear on the relevant Payment Dates specified in the Disbursement Offer, and calculated on the basis of Article 6.1 (Day count convention). If the period from the Disbursement Date to the first Payment
Date is [***] days or less then the payment of interest accrued during such period shall be postponed to the following Payment Date. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	18

	4.2	 Deferred Interest Fixed Rate 

In addition to the interest payable pursuant to Article 4.1 (Cash Interest Fixed Rate), interest shall accrue on the outstanding balance
of each Tranche under Credit A at the Deferred Interest Fixed Rate, and calculated on the basis of Article 6.1 (Day count convention), and such interest shall be due and payable on the Maturity Date of such Tranche or, where such Tranche is
cancelled or prepaid, on the date of cancellation or Prepayment Date. For the avoidance of doubt, any such interest shall not be capitalised and shall not bear interest. 
  

	4.3	 Profit Participation 

 

	 	(a)	 Subject to Paragraph (b) below and in addition to the interest payable pursuant to Articles 4.1 (Cash
Interest Fixed Rate) and Article 4.2 (Deferred Interest Fixed Rate) above and in consideration of the Bank making the Credit available to the Borrower in accordance with this Contract, the Borrower hereby grants and reserves for the
benefit of the Bank, a participation in the Drug Product Revenues for the period starting with the financial year 2023 until and including the financial year 2028 (6 years) (the “Profit Participation Period”) equal to:

  

	 	(i)	 [***]% of the annual Drug Product Revenues below EUR 100,000,000; 

 

	 	(ii)	 [***]% of the annual Drug Product Revenues between EUR 100,000,000 and EUR 250,000,000; and

  

	 	(iii)	 [***]% of the annual Drug Product Revenues between EUR 250,000,000 and EUR 500,000,000, 

(the “Profit Participation Payments”) and hereby undertakes to pay the respective Profit Participation Payments to the Bank
subject to the terms of this Contract. For the avoidance of doubt and by way of distinction from a silent partnership (stille Beteiligung), the Bank does not participate in any loss of the Borrower or any other Group Company. 

 

	 	(b)	 The obligation of the Borrower to make Profit Participation Payments pursuant to Paragraph (a) above shall
exist only for so long as the Profit Participation Cap is not reached. 

  

	 	(c)	 Each Profit Participation Payment shall become due and payable on the Payment Date immediately following the
delivery date of the Approved Financial Statement for the respective financial year. 

  

	 	(d)	 In case a Tranche is cancelled or prepaid pursuant to Articles 5.2 (Voluntary prepayment)
or 5.3 (Compulsory prepayment) within the Profit Participation Period, the Bank shall have the right (but not the obligation) to demand from the Borrower the payment of the present value of all future Profit Participation
Payments (up to the Profit Participation Cap), as determined by an Independent Expert (the “Expert Determination”). The costs related to the Expert’s Determination shall be borne by the Borrower and the
Expert’s Determination shall, in the absence of manifest error, be conclusive and binding on all parties to this Contract as to the matters to which it relates. The Borrower shall, within [***] Business Days of delivery of the Expert’s
Determination and upon the Bank’s demand, pay to the Bank the amount determined by the Expert Determination. 

  

	 	(e)	 The Borrower shall withhold any statutory withholding tax (Kapitalertragssteuer) from the Profit
Participation Payments and shall pay it to the competent tax office. 

  

	4.4	 Interest on overdue sums 

 

	 	(a)	 Without prejudice to Article 9 (Events of default) and by way of exception to Article 4.1 (Cash
Interest Fixed Rate) and Article 4.2 (Deferred Interest Fixed Rate), if the Borrower fails to pay any amount (other than any interest amount) payable by it under the Contract on its due date, interest shall accrue on any such overdue
amount (other than any interest amount) from the due date to the date of actual payment at an annual rate equal to: 

  

					
		  	Personalised Immunotherapies (EGFF).	  	19

	 	(i)	 for overdue sums related to a Tranche, the higher of (A) the applicable Cash Interest Fixed Rate and
Deferred Interest Fixed Rate plus [***]% ([***] basis points) or (B) EURIBOR plus [***]% ([***] basis points); 

  

	 	(ii)	 for overdue sums other than under sub-paragraph (a) of Article 4.4
(Interest on overdue sums) above, EURIBOR plus [***]% ([***] basis points), 

 and shall be payable in accordance
with the demand of the Bank. 
  

	 	(b)	 If the Borrower fails to pay any interest amount payable by it under this Contract on its due date, it shall
make a liquidated damages payment (pauschalierter Schadensersatz) from the due date up to the date of actual payment at an annual rate equal to the higher of (i) the applicable Fixed Rate plus [***]% ([***] basis points) or
(ii) EURIBOR plus [***]% ([***] basis points), provided that the Borrower shall have the right to prove that no damages have arisen, or that damages have not arisen in the asserted amount. The amount determined in accordance with this Article
4.4(b) shall be payable in accordance with the demand of the Bank 

 For the purpose of determining EURIBOR in relation to
this Article 4.4 (Interest on overdue sums), the relevant periods within the meaning of Schedule B (Definition of EURIBOR) shall be successive periods of one month commencing on the due date. 

If the overdue sum is in a currency other than the currency of the Loan, the relevant interbank rate that is generally retained by the Bank for
transactions in that currency plus [***]% ([***] basis points) shall apply, calculated in accordance with the market practice for such rate. 

ARTICLE 5 

Repayment 
  

	5.1	 Normal repayment 

The Borrower shall repay each Tranche, together with all other amounts outstanding under this Contract in relation to that Tranche, in a single
instalment on the Maturity Date of that Tranche. 
  

	5.2	 Voluntary prepayment 

 

	5.2.1	 Prepayment option 

 

	 	(a)	 Subject to Articles 5.2.2 (Prepayment Fee), 5.2.3 (Prepayment mechanics) and 5.4
(General), the Borrower may prepay all or part of any Tranche, together with accrued interest (including any interest under Article 4.2 (Deferred Interest Fixed Rate), any Profit Participation Payment (up to the Profit Participation
Cap) specified under Article 4.3 (Profit Participation), any Prepayment Fee and indemnities if any, upon giving a Prepayment Request with at least 30 (thirty) calendar days prior notice specifying: 

 

	 	(i)	 the Prepayment Amount; 

 

	 	(ii)	 the Prepayment Date; and 

 

	 	(iii)	 each Contract Number. 

 

	 	(b)	 The Prepayment Request shall be irrevocable. 

 

	5.2.2	 Prepayment Fee 

If the Borrower prepays a Tranche, the Borrower shall pay the relevant Prepayment Fee on the Prepayment Date. 

 

	5.2.3	 Prepayment mechanics 

Upon presentation by the Borrower to the Bank of a Prepayment Request, the Bank shall issue a Prepayment Notice to the Borrower, not later than
[***] days prior to the Prepayment Date. If the Borrower evidences to the Bank that – taking into account the time for procuring of the Expert Determination - takes longer than [***] days, the Borrower 

  

					
		  	Personalised Immunotherapies (EGFF).	  	20

 and the Bank will agree on a longer deadline. The Prepayment Notice shall specify the
Prepayment Amount, the accrued interest due thereon, the Prepayment Fee. If the Prepayment Notice specifies Prepayment Fee, it shall also specify the deadline by which the Borrower may accept the Prepayment Notice, and the Borrower must accept the
Prepayment Notice no later than such deadline as a condition to prepayment. 
 The Borrower shall make a prepayment in accordance with the
Prepayment Notice and shall accompany the prepayment by the payment of accrued interest (including any interest under Article 4.2 (Deferred Interest Fixed Rate) and any Profit Participation Payment specified under Sub-Paragraph (d) of Article 4.3 and Prepayment Fee or indemnity, if any, due on the Prepayment Amount, as specified in the Prepayment Notice, and shall identify each Contract Number in the prepayment transfer.

  

	5.3	 Compulsory prepayment 

 

	5.3.1	 Cost Reduction 

If the total cost of the Investment at completion by the final date specified in the Technical Description falls below the figure stated in
Recital (A) so that the amount of the Credit exceeds 50% (fifty per cent.) of such total cost, the Bank may forthwith, by notice to the Borrower, cancel the undisbursed portion of the Credit and/or demand prepayment of the Loan Outstanding up
to the amount by which the Credit exceeds 50% (fifty per cent.) of the total cost of the Investment. 
  

	5.3.2	 Change Events 

The Borrower shall promptly inform the Bank if: 
  

	 	(a)	 a Change-of-Control Event has
occurred or is likely to occur in respect of itself or a Guarantor; or 

  

	 	(b)	 a
Change-of-Law-Event has occurred or is likely to occur. 

In such case, or if the Bank has reasonable cause to believe that a
Change-of-Control Event or a Change-of-Law Event has occurred or is likely to occur, the
Borrower shall, on request of the Bank, consult with the Bank as to the impact of such event. If [***] days have passed since the date of such request and the Bank is of the reasonable opinion that the effects of such event cannot be mitigated to
its satisfaction, or in any event if a Change-of- Control Event or Change-of-Law Event has actually occurred, the Bank may by
notice to the Borrower, cancel the undisbursed portion of the Credit and/or demand prepayment of the Loan Outstanding, together with accrued interest (if any) and all other amounts accrued or outstanding under this Contract. 

 

	5.3.3	 Illegality 

If it becomes unlawful in any applicable jurisdiction for the Bank to perform any of its obligations as contemplated in this Contract or to
fund or maintain the Loan, the Bank shall promptly notify the Borrower and may immediately cancel the undisbursed portion of the Credit and/or demand prepayment of the Loan Outstanding, together with accrued interest (if any) and all other amounts
accrued or outstanding under this Contract. 
  

	5.3.4	 Disposals 

If the Borrower disposes of assets forming part of the Investment or shares in subsidiaries holding assets forming part of the Investment,
neither with the approval of the Bank nor in accordance with Sub-Paragraph (c) of Paragraph 7 (Disposal of assets) of Schedule H (General Undertakings), the Borrower shall apply all proceeds
of such disposal to prepay the Loan Outstanding (in part or in whole), together with accrued interest (if any), promptly following receipt of such proceeds. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	21

	5.3.5	 Expiry of Guarantee Agreement 

If (a) a Guarantee Agreement has a shorter duration than this Contract (as modified, extended and/or prolonged from time to time) and
(ii) on the date falling [***] days prior to the initial expiry date or, as the case may be, to any subsequent expiry date agreed under the Guarantee Agreement, the Borrower has failed to procure extension of the duration of the obligations of
the Guarantor under the Guarantee Agreement or, as the case may be, to replace the Guarantor by another guarantor on terms acceptable to the Bank or provide additional security for the Loan in manner, form and substance satisfactory to the Bank, the
Bank may, without prejudice to its other rights, require the Borrower to prepay the Loan Outstanding (in part or in whole), together with accrued interest (if any) and all other amounts accrued or outstanding under this Contract. 

 

	5.3.6	 Pari Passu to Non-EIB Financing 

 

	 	(a)	 If a Voluntary Non EIB Prepayment has occurred the Bank may, by notice to the Borrower, cancel the undisbursed
portion of the Credit and demand prepayment of the Loan; or 

  

	 	(b)	 If (i) a Voluntary Non EIB Prepayment is likely to occur, (ii) the Bank has requested a consultation
in respect of such Voluntary Non EIB Prepayment, (iii) the Borrower has complied with such request (to the satisfaction of the Bank) and (iv) at least [***] days have passed since the date of such request, the Bank may, by notice to the
Borrower, cancel the undisbursed portion of the Credit and demand prepayment of the Loan. 

  

	 	(c)	 If (i) a Voluntary Non EIB Prepayment is likely to occur, (ii) the Bank has requested a consultation
in respect of such Voluntary Non EIB Prepayment, (iii) the Borrower has not complied with such request within a reasonable period set by the Bank and (iv) at least [***] days have passed since the date of such request, the Bank may, by
notice to the Borrower, cancel the undisbursed portion of the Credit and demand prepayment of the Loan. 

 The proportion
of the Loan that the Bank may require to be prepaid shall in each case of Paragraphs (a) to (c) above be the same as the proportion that the prepaid amount of the Non-EIB Financing bears to the aggregate
outstanding amount of all Non-EIB Financing. 
  

	5.3.7	 Prepayment Fee 

In the case of a Prepayment Event in relation to a Tranche, the Borrower shall pay the relevant Prepayment Fee. 

 

	5.3.8	 Prepayment mechanics 

Any sum demanded by the Bank pursuant to Articles 5.3.1 (Cost Reduction) to 5.3.6 (Pari Passu to
Non-EIB Financing) shall be paid on the date indicated by the Bank in its notice of demand, such date being a date falling not less than [***] days from the date of the demand (or, if earlier, the last day
of any applicable grace period permitted by law in respect of the event in Article 5.3.3 (Illegality)). 
  

	5.4	 General 

 

	 	(a)	 A repaid or prepaid amount may not be reborrowed. 

 

	 	(b)	 If the Borrower prepays a Tranche on a date other than a relevant Payment Date, or if the Bank exceptionally
accepts, solely upon the Bank’s discretion, a Prepayment Request with prior notice of less than [***] calendar days, the Borrower shall pay to the Bank an administrative fee in such an amount as the Bank shall notify to the Borrower.

 ARTICLE 6 

Payments 
  

	6.1	 Day count convention 

Any amount due under this Contract and calculated in respect of a fraction of a year shall be determined based on a year of 360 (three hundred
and sixty) days and a month of 30 (thirty) days. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	22

	6.2	 Time and place of payment 

 

	 	(a)	 If neither this Contract nor the Bank’s demand specifies a due date, all sums other than sums of interest,
indemnity and principal are payable within [***] days of the Borrower’s receipt of the Bank’s demand. 

  

	 	(b)	 Each sum payable by the Borrower under this Contract shall be paid to the following account:

  

			
	Bank:	  	[***]
		
	City:	  	[***]
		
	Account number:	  	[***]
		
	SWIFT Code/BIC:	  	[***]
		
	Remark:	  	[***]

 or such other account notified by the Bank to the Borrower. 

 

	 	(c)	 The Borrower shall provide each Contract Number as a reference for each payment made under this Contract.

  

	 	(d)	 Any disbursements by and payments to the Bank under this Contract shall be made using account(s) acceptable to
the Bank. Any duly authorised financial institution in the jurisdiction where the Borrower is incorporated or where the Investment is undertaken is deemed an acceptable account bank and any account in the name of the Borrower with such account bank
is deemed acceptable to the Bank. 

  

	6.3	 No set-off by the Borrower 

All payments to be made by the Borrower under this Contract shall be calculated and be made without (and free and clear of any deduction for) set-off or counterclaim, unless the counterclaim is undisputed (unbestritten) or has been confirmed in a final non-appealable judgement (rechtskräftig
festgestellt). 
  

	6.4	 Disruption to Payment Systems 

If either the Bank determines (in its discretion) that a Disruption Event has occurred or the Bank is notified by the Borrower that a
Disruption Event has occurred: 
  

	 	(a)	 the Bank may, and shall if requested to do so by the Borrower, consult with the Borrower with a view to
agreeing with the Borrower such changes to the operation or administration of the Contract as the Bank may deem necessary in the circumstances; 

  

	 	(b)	 the Bank shall not be obliged to consult with the Borrower in relation to any changes mentioned in Sub-Paragraph (a) of Article 6.4 (Disruption to Payment Systems) above if, in its opinion, it is not practicable to do so in the circumstances and, in any event, shall have no obligation to agree to such
changes; and 

  

	 	(c)	 the Bank shall not be liable for any damages, costs or losses whatsoever arising as a result of a Disruption
Event or for taking or not taking any action pursuant to or in connection with this Article 6.4 (Disruption to Payment Systems). 

  

	6.5	 Application of sums received 

 

	6.5.1	 General 

Sums received from the Borrower shall only discharge its payment obligations if and when received in accordance with the terms of this
Contract. 
  

	6.5.2	 Partial payments 

If the Bank receives a payment that is insufficient to discharge all the amounts then due and payable by the Borrower under this Contract, the
Bank shall apply that payment in or towards payment of: 

  

					
		  	Personalised Immunotherapies (EGFF).	  	23

	 	(a)	 first, any unpaid fees, costs, indemnities and expenses due under this Contract; 

 

	 	(b)	 secondly, any accrued interest due but unpaid under this Contract; 

 

	 	(c)	 thirdly, any principal due but unpaid under this Contract; 

 

	 	(d)	 fourthly, any Profit Participation Payments due but unpaid under this Contract; and 

 

	 	(e)	 lastly, any other sum due but unpaid under this Contract. 

 

	6.5.3	 Allocation of sums related to Tranches 

In case of receipt of sums which cannot be identified as applicable to a specific Tranche, and on which there is no agreement between the Bank
and the Borrower on their application, the Bank may apply these between Tranches at its discretion. 
 ARTICLE 7 

Borrower undertakings and representations 
  

	 	(a)	 The Borrower makes the representations and warranties set out in Schedule G (Representations and
Warranties) to the Bank on the date of this Contract in respect of itself and, where applicable, the other Obligors. 

  

	 	(b)	 The Repeating Representations are deemed to be made by the Borrower (in respect of itself and, where
applicable, the other Obligors) on the date of each Disbursement Acceptance, each Disbursement Date and each Payment Date by reference to the facts and circumstances then existing. 

 

	 	(c)	 The undertakings in Schedule H (General Undertakings) and Schedule I (Information and Visits)
remain in force from the date of this Contract for so long as any amount is outstanding under this Contract or the Credit is available. 

ARTICLE 8 

Charges and expenses 
  

	8.1	 Taxes, duties and fees 

 

	 	(a)	 The Borrower shall pay all Taxes, duties, fees (including any notarial and
pre-agreed legal fees) and other impositions of whatsoever nature, including stamp duty and registration fees, arising out of the execution or implementation of each Finance Document or any related document
and the creation, perfection, registration of any security for the Loan. 

  

	 	(b)	 The Borrower shall pay all Taxes, duties fees (including any notarial and legal fees) and other impositions
whatsoever nature, including stamp duty and registration fees, arising out of the amendment, preservation of any rights under or enforcement of any Finance Document and any security for the Loan to the extent applicable. 

 

	 	(c)	 The Borrower shall pay all principal, interest, Profit Participation Payments, indemnities and other amounts
due under this Contract gross without any withholding or deduction of any national or local impositions whatsoever, provided that if the Borrower is required by law or an agreement with a governmental authority or otherwise to make any such
withholding or deduction, it will gross up the payment to the Bank so that after withholding or deduction, the net amount received by the Bank is equivalent to the sum due. 

 

	8.2	 Other charges 

The Borrower shall bear all charges and expenses, including any notarial and legal fees, professional, banking or exchange charges incurred in
connection with the preparation, execution, implementation, enforcement and termination of the Finance Documents (including, but not limited to, any Guarantee Agreement entered into pursuant to Paragraph 

  

					
		  	Personalised Immunotherapies (EGFF).	  	24

 16 (Guarantees) of Schedule H (General Undertakings)) or any related document,
any amendment, supplement or waiver in respect of the Finance Documents or any related document, and in the amendment, creation, management, enforcement and realisation of any security for the Loan. 

The Bank shall provide documentary support for any such charges or expenses upon the Borrower’s request. 

 

	8.3	 Increased costs, indemnity and set-off

  

	 	(a)	 The Borrower shall pay to the Bank any costs or expenses incurred or suffered by the Bank as a consequence of
the introduction of or any change in (or in the interpretation, administration or application of) any law or regulation or compliance with any law or regulation which occurs after the date of this Contract, in accordance with or as a result of which
(i) the Bank is obliged to incur additional costs in order to fund or perform its obligations under this Contract, or (ii) any amount owed to the Bank under this Contract or the financial income resulting from the granting of the Credit or
the Loan by the Bank to the Borrower is reduced or eliminated. This Paragraph (a) does not apply to the extent any such costs or expenses are attributable to the wilful breach by the Bank of any law or regulation. 

 

	 	(b)	 Without prejudice to any other rights of the Bank under this Contract or under any applicable law, the Borrower
shall indemnify and hold the Bank harmless from and against any loss incurred as a result of any full or partial discharge that takes place in a manner other than as expressly set out in this Contract. 

 

	 	(c)	 The Bank may set off any matured obligation due from the Borrower under any Finance Document (to the extent
beneficially owned by the Bank) against any satisfiable (erfüllbar) obligation (within the meaning of Section 387 BGB) owed by the Bank to the Borrower regardless of the place of payment, booking branch or currency of either
obligation. If the obligations are in different currencies, the Bank may convert either obligation at a market rate of exchange in its usual course of business for the purpose of the set-off. If either
obligation is unliquidated or unascertained, the Bank may set off in an amount estimated by it in good faith to be the amount of that obligation. 

ARTICLE 9 

Events of default 
  

	9.1	 Right to demand repayment 

The Bank may demand (in writing) without prior notice or any judicial or extra judicial step immediate repayment by the Borrower of all or part
of the Loan Outstanding (as requested by the Bank), together with accrued interest, any Profit Participation Payment, any Prepayment Fee and all other accrued or outstanding amounts under this Contract, if: 

 

	 	(a)	 any amount payable pursuant to any Finance Document is not paid on the due date at the place and in the
currency in which it is expressed to be payable, unless (i) its failure to pay is caused by an administrative or technical error or a Disruption Event and (ii) payment is made within [***] Business Days of its due date;

  

	 	(b)	 any information or document given to the Bank by or on behalf of any Obligor or any representation, warranty or
statement made or deemed to be made by the Borrower in any Finance Document, pursuant to any Finance Document or for the purposes of entering into any Finance Document is or proves to have been incorrect, incomplete or misleading in any material
respect; 

  

	 	(c)	 following any default of any Obligor in relation to any loan, or any obligation arising out of any financial
transaction, other than the Loan, 

  

					
		  	Personalised Immunotherapies (EGFF).	  	25

	 	(i)	 such Obligor is required or is capable of being required or will, following expiry of any applicable
contractual grace period, be required or be capable of being required to prepay, discharge, close out or terminate ahead of maturity such other loan or obligation; or 

 

	 	(ii)	 any financial commitment for such other loan or obligation is cancelled or suspended; and

  

	 	(iii)	 such other loans or obligations or commitments falling under
sub-paragraphs (i) and/or (ii) above are in an aggregate principal amount in excess of EUR [***] euro) or its equivalent in any other currency or currencies; 

 

	 	(d)	 any Obligor is unable or admits inability to pay its debts as they fall due, or suspends any of its debts, or
makes or seeks to make a composition with its creditors including a moratorium, or commences negotiations with one or more of its creditors with a view to rescheduling any of its financial indebtedness; 

 

	 	(e)	 any corporate action, legal proceedings or other procedure or step is taken in relation to the suspension of
payments, a moratorium of any indebtedness, dissolution, administration or reorganisation (by way of voluntary arrangement, scheme of arrangement or otherwise) or an order is made or an effective resolution is passed for the winding up of any
Obligor, or if any Obligor takes steps towards a substantial reduction in its capital, is declared insolvent or ceases or resolves to cease to carry on the whole or any substantial part of its business or activities or any situation similar to any
of the above occurs under any applicable law; 

  

	 	(f)	 any Obligor incorporated in Germany is unable to pay its debts as they fall due (zahlungsunfähig)
within the meaning of Section 17 InsO or is overindebted (überschuldet) within the meaning of Section 19 InsO; 

  

	 	(g)	 an encumbrancer takes possession of, or a receiver, liquidator, administrator, administrative receiver or
similar officer is appointed, whether by a court of competent jurisdiction or by any competent administrative authority or by any person, of or over, any part of the business or assets of any Obligor or any property forming part of the Investment;

  

	 	(h)	 any Obligor defaults in the performance of any obligation in respect of any other loan granted by the Bank or
financial instrument entered into with the Bank; 

  

	 	(i)	 any Obligor defaults in the performance of any obligation in respect of any other loan made to it from the
resources of the Bank or the European Union; 

  

	 	(j)	 any distress, execution, sequestration or other process is levied or enforced upon the property of any Obligor
or any property forming part of the Investment and is not discharged or stayed within [***] days; 

  

	 	(k)	 a Material Adverse Change occurs, as compared with the position at the date of this Contract;

  

	 	(l)	 it is or becomes unlawful for any Obligor to perform any of its obligations under the Finance Documents, or the
Finance Documents are not effective in accordance with its terms or is alleged by any Obligor to be ineffective in accordance with its terms; or 

  

	 	(m)	 any Obligor fails to comply with any other provision under the Finance Documents (including, without
limitation, each of the undertakings in Schedule H (General Undertakings) and Schedule I (Information and Visits)), unless the non-compliance or circumstance giving rise to the non-compliance is capable of remedy and is remedied within [***] Business Days from the earlier of the Borrower becoming aware of the non-compliance and a notice served by the
Bank on the Borrower. 

  

	9.2	 Other rights at law 

Article 9.1 (Right to demand repayment) shall not restrict any other right of the Bank at law (e.g. pursuant to Sections 314 or 490 BGB)
to require prepayment of the Loan Outstanding together with any sum, interest, fee or accrued amount, irrespectively of the fact that the Contract might convert into a so called settlement contractual relationship
(Abwicklungsschuldverhältnis). 

  

					
		  	Personalised Immunotherapies (EGFF).	  	26

	9.3	 Prepayment Fee 

In case of demand under Article 9.1 (Right to demand repayment), the Borrower shall pay the Bank the amount demanded together with the
relevant Prepayment Fee. 
  

	9.4	 Non-Waiver 

No failure or delay or single or partial exercise by the Bank in exercising any of its rights or remedies under this Contract shall be
construed as a waiver of such right or remedy. The rights and remedies provided in this Contract are cumulative and not exclusive of any rights or remedies provided by law. 

ARTICLE 10 

Law and jurisdiction, miscellaneous 
  

	10.1	 Governing Law 

This Contract and any non-contractual obligations arising out of or in connection with it shall be
governed by the laws of Germany. 
  

	10.2	 Jurisdiction 

 

	 	(a)	 The courts of Frankfurt am Main, Germany, have exclusive jurisdiction to settle any dispute (a
“Dispute”) arising out of or in connection with this Contract (including a dispute regarding the existence, validity or termination of this Contract or the consequences of its nullity) or any
non-contractual obligation arising out of or in connection with this Contract. 

  

	 	(b)	 The parties agree that the courts of Frankfurt am Main, Germany, are the most appropriate and convenient courts
to settle Disputes between them and, accordingly, that they will not argue to the contrary. 

  

	 	(c)	 This Article 10.2 (Jurisdiction) is for the benefit of the Bank only. As a result and notwithstanding Sub-Paragraph (a) above, it does not prevent the Bank from taking proceedings relating to a Dispute in any other courts with jurisdiction. To the extent allowed by law, the Bank may take concurrent proceedings
in any number of jurisdictions. 

  

	10.3	 Place of performance 

Unless otherwise specifically agreed by the Bank in writing, the place of performance under this Contract, shall be the seat of the Bank. 

 

	10.4	 Evidence of sums due 

In any legal action arising out of this Contract the certificate of the Bank as to any amount or rate due to the Bank under this Contract
shall, in the absence of manifest error, be prima facie evidence of such amount or rate. 
  

	10.5	 Third party rights 

A person who is not a party to this Contract has no right to enforce or to enjoy the benefit of any term of this Contract (no echter Vertrag
zugunsten Dritter within the meaning of Section 328 para. 1 BGB). 

  

					
		  	Personalised Immunotherapies (EGFF).	  	27

	10.6	 Entire Agreement 

This Contract (together with the other Finance Documents) constitutes the entire agreement between the Bank and the Borrower in relation to the
provision of the Credit hereunder, and supersedes any previous agreement, whether express or implied, on the same matter. 
  

	10.7	 Invalidity 

If at any time any term of this Contract is or becomes illegal (nichtig), invalid or unenforceable in any respect, or this Contract is
or becomes ineffective (unwirksam) in any respect, under the laws of any jurisdiction, such illegality (Nichtigkeit), invalidity, unenforceability or ineffectiveness (Unwirksamkeit) shall indisputably (unwiderlegbar) not
affect: 
  

	 	(a)	 the legality, validity or enforceability in that jurisdiction of any other term of this Contract or the
effectiveness in any other respect of this Contract in that jurisdiction; or 

  

	 	(b)	 the legality, validity or enforceability in other jurisdictions of that or any other term of this Contract or
the effectiveness of this Contract under the laws of such other jurisdictions, 

 without any party to this Contract having
to argue (darlegen) and prove (beweisen) such parties’ intent to uphold this Contract even without the void, invalid or ineffective provisions. 

The illegal, invalid, unenforceable or ineffective provision shall be deemed replaced by such legal, valid, enforceable and effective provision
that in legal and economic terms comes closest to what the Parties intended or would have intended in accordance with the purpose of this Contract if they had considered the point at the time of conclusion of this Contract. The same applies in the
event that this Contract or any other Finance Document does not contain a provision which it needs to contain in order to achieve the economic purpose as expressed herein (Regelungslücke). 

 

	10.8	 Amendments 

Any amendment to this Contract (including this Article 10.8) or any other Finance Document shall be made in writing (or in notarial form, if
required) and shall be signed by the parties hereto. 
  

	10.9	 Counterparts 

This Contract may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument. Each
counterpart is an original, but all counterparts shall together constitute one and the same instrument. 
  

	10.10	 Assignment and transfer by the Bank 

 

	 	(a)	 Subject to sub-paragraph (b) of this Article 10.10 (Assignment
and transfer by the Bank), the consent of the Borrower is required for an assignment or transfer (by way of assumption of contract (Vertragsübernahme), sub-participation or otherwise) by the
Bank of all or part of its rights, benefits or obligations under the Finance Documents, unless the assignment or transfer: 

  

	 	(i)	 is to a Bank Affiliate; or 

 

	 	(ii)	 is made at a time when an Event of Default has occurred and is continuing; or 

 

	 	(iii)	 is made in respect of a sub-participation or securitisation (or similar
transaction of broadly equivalent economic effect) where the Bank remains the lender of record of the Loan. 

  

	 	(b)	 The consent of the Borrower to an assignment or transfer must not be unreasonably withheld or delayed. The
Borrower will be deemed to have given its consent [***] Business Days after the Bank has requested it unless consent is expressly refused by the Borrower within that time. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	28

	 	(c)	 The Bank shall have the right to disclose all information relating to or concerning the Borrower, the Group,
the Finance Documents and the Loan in connection with or in contemplation of any such assignment or transfer. 

 For the
purpose of this Article 10.10 (Assignment and transfer by the Bank): 
 “Affiliate” means any entity directly or
indirectly Controlling, Controlled by or under common Control with the Bank. 
 “Bank Affiliate” means an Affiliate of the
Bank and any other entity or platform initiated, managed or advised by the Bank. 
 ARTICLE 11 

Final Articles 
  

	11.1	 Notices 

 

	11.1.1	 Form of notice 

 

	 	(a)	 Any notice or other communication given under this Contract must be in writing and, unless otherwise stated,
may be made by letter and electronic mail. 

  

	 	(b)	 Notices and other communications for which fixed periods are laid down in this Contract or which themselves fix
periods binding on the addressee, may be made by hand delivery, registered letter or by electronic mail. Such notices and communications shall be deemed to have been received by the other party: 

 

	 	(i)	 on the date of delivery in relation to a hand-delivered or registered letter; 

 

	 	(ii)	 in the case of any electronic mail, when the electronic mail is received in readable form.

  

	 	(c)	 Any notice provided by the Borrower or a Guarantor to the Bank by electronic mail shall: 

 

	 	(i)	 mention each Contract Number in the subject line; and 

 

	 	(ii)	 be in the form of a non-editable electronic image (pdf, tif or other
common non-editable file format agreed between the parties) of the notice signed by one or more Authorised Signatories of the Borrower as appropriate, attached to the electronic mail. 

 

	 	(d)	 Notices issued by the Borrower pursuant to any provision of this Contract shall, where required by the Bank, be
delivered to the Bank together with satisfactory evidence of the authority of the person or persons authorised to sign such notice on behalf of the Borrower and the authenticated specimen signature of such person or persons, unless such person is
listed in the then current List of Authorised Signatories. 

  

	 	(e)	 Without affecting the validity of electronic mail or communication made in accordance with this Article 11.1
(Notices), the following notices, communications and documents shall also be sent by registered letter to the relevant party at the latest on the immediately following Business Day: 

 

	 	(i)	 Disbursement Acceptance; 

 

	 	(ii)	 any notices and communication in respect of the cancellation of a disbursement of any Tranche, Prepayment
Request, Prepayment Notice, Event of Default, any demand for prepayment, and 

  

	 	(iii)	 any other notice, communication or document required by the Bank. 

 

	 	(f)	 The parties agree that any above communication (including via electronic mail) is an accepted form of
communication, shall constitute admissible evidence in court and shall have the same evidential value as an agreement under hand. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	29

	 	(g)	 Any communication or document made or delivered to the Borrower in accordance with this Article 11.1
(Notices) will be deemed to have been made or delivered to each of the Obligors or any other member of the Group party to a Finance Document. Each Obligor incorporated in Germany, for this purpose, appoints the Borrower as its receipt agent
(Empfangsboten). 

  

	11.1.2	 Addresses 

The address and electronic mail address (and the department or officer, if any, for whose attention the communication is to be made) of each
party for any communication to be made or document to be delivered under or in connection with this Contract is: 
  

			
	For the Bank	  	 Attention: OPS/ENPST/3-GC&IF

 
 100 boulevard Konrad Adenauer

 
 L-2950 Luxembourg

 

		  	 Email address: [***]
  

	For the Borrower	  	 Attention: Department/Division
  

Chief Financial Officer (CFO)
  

An der Goldgrube 12
  

		  	 D-55131 Mainz
  

Germany
  

		  	Email address: [***]

  

	11.1.3	 Demand after notice to remedy 

The Bank and the Borrower shall promptly notify the other party in writing of any change in their respective communication details. 

 

	11.2	 English language 

 

	 	(a)	 Any notice or communication given under or in connection with this Contract must be in English.

  

	 	(b)	 To the extent required by local law, Security Documents shall be in the language required under the relevant
local law; in particular any documentation in relation to the Land Charge to be filed with the land register (Grundbuchamt) shall be in German. 

  

	 	(c)	 All other documents provided under or in connection with this Contract must be: 

 

	 	(i)	 in English; or 

  

	 	(ii)	 if not in English, and if so required by the Bank, accompanied by a certified English translation and, in this
case, the English translation will prevail. 

  

	11.3	 Conclusion of this Contract (Vertragsschluss)

  

	 	(a)	 The parties to this Contract may choose to conclude this Contract by an exchange of signed signature page(s),
transmitted by any means of telecommunication (telekommunikative Übermittlung) such as by way of electronic photocopy. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	30

	 	(b)	 If the parties to this Contract choose to conclude this Contract pursuant to this Article 11.3 (Conclusion
of this Contract (Vertragsschluss)), they will transmit the signed signature page(s) of this Contract to Noerr LLP, Börsenstr. 1, 60313 Frankfurt am Main, Germany, [***] (each a “Recipient”). The Contract will be considered
concluded once a Recipient has actually received the signed signature page(s) (Zugang der Unterschriftsseite(n)) from all Parties (whether electronic photocopy or other means of telecommunication and at the time of the receipt of the last
outstanding signature page(s) by such one Recipient). 

  

	 	(c)	 For the purposes of this Article 11.3 (Conclusion of this Contract (Vertragsschluss)) only, the parties
to this Contract appoint each Recipient as their attorney (Empfangsvertreter) and expressly allow (gestatten) each Recipient to collect the signed signature page(s) from all and for all parties to this Contract. For the avoidance of
doubt, each Recipient will have no further duties connected with its position as Recipient. In particular, each Recipient may assume the conformity to the authentic original(s) of the signature page(s) transmitted to it by means of
telecommunication, the genuineness of all signatures on the original signature page(s) and the signing authority of the signatories. (d) For the purposes of proof and confirmation, each party to this Contract has to provide the Recipients with
original signature page(s) promptly after signing this Contract in accordance with this Article 11.3 (Conclusion of this Contract (Vertragsschluss)). The Bank may demand that the Borrower subsequently sign one or more copies of this Contract.

  

					
		  	Personalised Immunotherapies (EGFF).	  	31

 IN WITNESS WHEREOF the parties hereto have caused this Contract to be executed in three
(3) originals (two (2) originals for the Bank and one (1) original for the Borrower) in the English language. 
  

					
	Signed for and on behalf of	  	Signed for and on behalf of
		
	EUROPEAN INVESTMENT BANK	  	BIONTECH SE
			
	[***]	  	[***]	  	[***]

  

					
		  	Personalised Immunotherapies (EGFF).	  	32

 Schedule A 

Investment Specification and Reporting 

A.1 Technical Description 

Purpose, Location 
 [***] 

Description 
 [***] 

Calendar 
 [***] 

A.2 Information Duties 
 The
information below has to be sent to the Bank under the responsibility of: 
  

			
		  	Financial & Technical Contact
		
	Company	  	BioNTech SE
		
	Contact person	  	[***]
		
	Title	  	[***]
		
	Address	  	An der Goldgrube 12, D-55131 Mainz, Germany
		
	Phone	  	[***]
		
	Email	  	[***]

 The above-mentioned contact person is the responsible contact for the time being. The Borrower shall inform the EIB
immediately in case of any change. 
 Information on the project’s implementation 

The Borrower shall deliver to the Bank the following information on project progress during implementation at the latest by the deadline(s) indicated below.

  

					
	 Document / information
	  	 Deadline
	  	 Frequency of reporting

	Project Progress Report	  	[***]	  	Bi-annually
	[***]

  

					
		  	Personalised Immunotherapies (EGFF).	  	33

 Information on the end of works and first year of operation 

The Borrower shall deliver to the Bank the following information on project completion and initial operation at the latest by the deadline indicated below.

  

					
		  	Personalised Immunotherapies (EGFF).	  	34

			
	 Document / information
	  	 Date of delivery to the Bank

	[***]	  	[***]

  

			
	Language of reports	  	English

  

					
		  	Personalised Immunotherapies (EGFF).	  	35

 Schedule B 

Definition of EURIBOR 

“EURIBOR” means: 
  

	(a)	 in respect of a relevant period of less than one month, the Screen Rate (as defined below) for a term of one
month; 

  

	(b)	 in respect of a relevant period of one or more months for which a Screen Rate is available, the applicable
Screen Rate for a term for the corresponding number of months; and 

  

	(c)	 in respect of a relevant period of more than one month for which a Screen Rate is not available, the rate
resulting from a linear interpolation by reference to two Screen Rates, one of which is applicable for a period next shorter and the other for a period next longer than the length of the relevant period, 

(the period for which the rate is taken or from which the rates are interpolated being the “Representative Period”). 

For the purposes of Paragraphs (b) and (c) above, “available” means the rates, for given maturities, that are calculated and
published by Global Rate Set Systems Ltd (GRSS), or such other service provider selected by the European Money Markets Institute (EMMI), under the sponsorship of EMMI and EURIBOR ACI, or any successor to that function of EMMI and EURIBOR ACI as
determined by the Bank. 
 “Screen Rate” means the rate of interest for deposits in EUR for the relevant period as published
at 11h00, Brussels time, or at a later time acceptable to the Bank on the day (the “Reset Date”) which falls 2 (two) Relevant Business Days prior to the first day of the relevant period, on Reuters page EURIBOR 01 or its successor
page or, failing which, by any other means of publication chosen for this purpose by the Bank. 
 If such Screen Rate is not so published,
the Bank shall request the principal euro-zone offices of four major banks in the euro-zone, selected by the Bank, to quote the rate at which EUR deposits in a comparable amount are offered by each of them as at approximately 11h00, Brussels time,
on the Reset Date to prime banks in the euro-zone interbank market for a period equal to the Representative Period. If at least 2 (two) quotations are provided, the rate for that Reset Date will be the arithmetic mean of the quotations. 

If fewer than 2 (two) quotations are provided as requested, the rate for that Reset Date will be the arithmetic mean of the rates quoted by
major banks in the euro-zone, selected by the Bank, at approximately 11h00, Brussels time, on the day which falls 2 (two) Relevant Business Days after the Reset Date, for loans in EUR in a comparable amount to leading European Banks for a period
equal to the Representative Period. 
 If no rate is available as provided above, EURIBOR shall be the rate (expressed as a percentage rate
per annum) which is determined by the Bank to be the all-inclusive cost to the Bank for the funding of the relevant Tranche based upon the then applicable internally generated Bank reference rate or an
alternative rate determination method reasonably determined by the Bank. 
 For the purposes of the foregoing definitions: 

 

	(a)	 All percentages resulting from any calculations referred to in this Schedule B (Definition of EURIBOR)
will be rounded, if necessary, to the nearest one thousandth of a percentage point, with halves being rounded up. 

  

	(b)	 The Bank shall inform the Borrower without delay of the quotations received by the Bank. 

 

	(c)	 If any of the foregoing provisions becomes inconsistent with provisions adopted under the aegis of EMMI and
EURIBOR ACI (or any successor to that function of EMMI and EURIBOR ACI as determined by the Bank), the Bank may by notice to the Borrower amend the provision to bring it into line with such other provisions. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	36

 Schedule C 

Form of Disbursement Offer/Acceptance 

 

			
	To:	  	BioNTech SE
		
	From:	  	European Investment Bank
		
	Date:	  	

  

			
	Subject: Disbursement Offer/Acceptance for the Finance Contract between European Investment Bank and BioNTech SE dated 12 December 2019 (the “Finance Contract”)
	Contract Number [***] and [***]	  	Serapis Number [***]

  
  

Dear Sirs, 
 We refer to the Finance Contract. Terms defined in
the Finance Contract have the same meaning when used in this letter. 
 Following your request for a Disbursement Offer from the Bank, in accordance with
Article 2.2.2 (Disbursement Offer) of the Finance Contract, we hereby offer to make available to you the following Tranche: 
  

	(a)	 Credit: [A / B] 

  

	(b)	 Amount to be disbursed: 

 

	(c)	 Disbursement Date: 

  

	(d)	 Cash Interest Fixed Rate (if applicable): 

 

	(e)	 Deferred Interest Fixed Rate (if applicable): 

 

	(f)	 Payment Dates / interest periods: [●] / quarterly 

 

	(g)	 Terms and frequency for repayment of principal: 

 

	(h)	 Maturity Date: 

To make the Tranche available subject to the terms and conditions of the Finance Contract, the Bank must receive a Disbursement Acceptance in the form of a
copy of this Disbursement Offer duly signed on your behalf, to the following electronic mail [●] no later than the Disbursement Acceptance Deadline of [time], Luxembourg time, on [date]. 

The Disbursement Acceptance below must be signed by an Authorised Signatory and must be fully completed as indicated, to include the details of the
Disbursement Account. 
 If not duly accepted by the above stated time, the offer contained in this document shall be deemed to have been refused and shall
automatically lapse. 
 If you do accept the Tranche as described in this Disbursement Offer, all the related terms and conditions of the Finance Contract
shall apply, in particular, the provisions of Article 2.5 (Conditions of Disbursement). 
 Yours faithfully, 

EUROPEAN INVESTMENT BANK 

  

					
		  	Personalised Immunotherapies (EGFF).	  	37

 [On letterhead of the Borrower] 

We hereby accept the above Disbursement Offer for and on behalf of the Borrower: 
  

                          
                                         
                          

Date: 
 Account to be credited: 

Account N°: 
 Account Holder/Beneficiary: 

(please, provide IBAN format if the country is included in IBAN Registry published by SWIFT, otherwise an appropriate format in line with the local banking
practice should be provided) 
 Bank name, identification code (BIC) and address: 

Payment details to be provided: 
 Please transmit information
relevant to: 
 Name(s) of the Borrower’s Authorised Signatory(ies): 
  

 
 Signature(s) of the Borrower’s Authorised
Signatory(ies): 
 Name(s)/Title(s): 

 

IMPORTANT NOTICE TO THE BORROWER: 

BY COUNTERSIGNING ABOVE YOU CONFIRM THAT THE LIST OF AUTHORISED SIGNATORIES AND ACCOUNTS PROVIDED TO THE BANK WAS DULY UPDATED PRIOR TO THE
PRESENTATION OF THE ABOVE DISBURSEMENT OFFER BY THE BANK. 
 IN THE EVENT THAT ANY SIGNATORIES OR ACCOUNTS
APPEARING IN THIS DISBURSEMENT ACCEPTANCE ARE NOT INCLUDED IN THE LATEST LIST OF AUTHORISED SIGNATORIES AND ACCOUNTS RECEIVED BY THE BANK, THE ABOVE DISBURSEMENT OFFER SHALL BE DEEMED AS NOT HAVING BEEN MADE. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	38

 Schedule D 

Form of Drawdown Certificate 
  

					
	To:	  	European Investment Bank From:	  	
			
	Date:	  	BioNTech SE	  	

  

					
	Subject:	  	Finance Contract between European Investment Bank and BioNTech SE dated 12 December 2019 (the “Finance Contract”)
			
		  	Contract Number [***] and [***]	  	Serapis Number [***]

  
  

Dear Sirs, 
 Terms defined in the Finance Contract have the same
meaning when used in this letter. 
 For the purposes of Article 2.5 (Conditions of Disbursement) of the Finance Contract we hereby certify to you as
follows: 
  

	(a)	 no Prepayment Event has occurred and is continuing; 

 

	(b)	 no security of the type prohibited under Paragraph 23 (Negative pledge) of Schedule H (General
Undertakings) has been created or is in existence; 

  

	(c)	 there has been no material change to any aspect of the Investment or in respect of which we are obliged to
report under the Finance Contract, save as previously communicated by us; 

  

	(d)	 no Default, Event of Default or a Prepayment Event other than pursuant to Article 5.3.1 (Cost Reduction)
of the Finance Contract has occurred or is continuing, or would, in each case, result from the disbursement of the proposed Tranche; 

  

	(e)	 no litigation, arbitration administrative proceedings or investigation is current or to our knowledge and
belief (having made due and careful enquiry) is threatened or pending before any court, arbitral body or agency which has resulted or if adversely determined is reasonably likely to result in a Material Adverse Change, nor is there subsisting
against us or any of our subsidiaries any unsatisfied judgement or award; 

  

	(f)	 the Repeating Representations are correct in all respects; 

 

	(g)	 no Material Adverse Change has occurred, as compared with the situation at the date of the Finance Contract;
and 

  

	(h)	 the borrowing of the Credit, or any part thereof, by the Borrower is within the corporate powers of the
Borrower. 

 Yours faithfully, 
 For and on
behalf of BioNTech SE 
 Date: 
 Name(s)/Title(s): 

  

					
		  	Personalised Immunotherapies (EGFF).	  	39

 Schedule E 

Form of Compliance Certificate 
  

					
	To:	  	European Investment Bank	  	
			
	From:	  	BioNTech SE	  	
			
	Date:	  		  	

  

					
	Subject:	  	Finance Contract between European Investment Bank and BioNTech SE dated 12 December 2019 (the “Finance Contract”)
			
		  	Contract Number [***] and [***]	  	Serapis Number [***]

  
  

Dear Sirs, 
 We refer to the Finance Contract. This is a
Compliance Certificate. Terms defined in the Finance Contract have the same meaning when used in this Compliance Certificate. 
 We hereby confirm: 

 

	(a)	 [insert information regarding asset disposal]; 

 

	(b)	 [no security of the type prohibited under Paragraph 23 (Negative pledge) of Schedule H (General
Undertakings) has been created or is in existence; and] 

  

	(c)	 [no Default, Event of Default or a Prepayment Event other than pursuant to Article 5.3.1 (Cost Reduction) of
the Finance Contract has occurred or is continuing. [If this statement cannot be made, this certificate should identify any potential event of default that is continuing and the steps, if any, being taken to remedy it]. 

Yours faithfully, 
 For and on behalf of BioNTech SE 

Date: 
 Name(s)/Title(s): 

  

					
		  	Personalised Immunotherapies (EGFF).	  	40

 Schedule F 

Part A - Initial Documentary Conditions Precedent and Credit A Conditions Precedents 

 

	(a)	 The following, duly executed Finance Documents: 

 

	 	(i)	 originals of this Contract; 

 

	 	(ii)	 originals of the Guarantee Agreements; 

 

	 	(iii)	 originals of each Security Document, including an enforceable copy (vollstreckbare Ausfertigung) of the
Land Charge Creation Deed; and 

  

	 	(iv)	 original of the Fee Letters. 

 

	(b)	 The constitutional documents of each Obligor, being in relation to an Obligor incorporated in Germany
electronic copies of (i) an up-to-date (dated no earlier than the date falling [***] days before the Disbursement Date) electronic extract from the commercial
register (Handelsregisterauszug), (ii) its articles of association (Gesellschaftsvertrag) and copies of any by-laws and rules of procedures (Geschäftsordnungen) and (iii) its
list of shareholders (Gesellschafterliste) or list of supervisory board members (if applicable). 

  

	(c)	 A copy of the resolution of the competent body (board of directors (Vorstand), supervisory board
(Aufsichtsrat), administrative board (Verwaltungsrat) or general meeting of shareholders (Gesellschafterversammlung)) of each Obligor: 

  

	 	(i)	 approving the terms of, and the transactions contemplated by, the Finance Documents to which it is a party as
and duly authorising the execution of the Finance Documents to which it is a party; 

  

	 	(ii)	 duly authorising the relevant signatories to execute the Finance Documents to which it is a party on its
behalf; and 

  

	 	(iii)	 authorising a signatory or signatories, on its behalf, to sign and/or despatch all documents and notices to be
signed and/or despatched by it under or in connection with the Finance Documents to which it is a party. 

  

	(d)	 An up-to-date (dated no earlier
than the date falling [***] days before the Disbursement Date) structure chart showing the Group certified as being complete and correct by an Authorised Signatory of the Borrower. 

 

	(e)	 A certificate of an Authorised Signatory of each Obligor certifying that each copy document relating to it
specified in Paragraph (b) and (c) of this Part A of Schedule F (Initial Documentary Conditions Precedent and Credit A Conditions Precedents) is correct, complete and in full force and effect as at a date no earlier than the date falling
14 (fourteen) days before the first Disbursement Date. 

  

	(f)	 The List of Authorised Signatories and Accounts. 

 

	(g)	 A legal enforceability opinion of Noerr LLP, addressed to the Bank on the legality, validity and enforceability
of the Finance Documents and including statements as to no consents, registrations or filings are required and no stamp duty is to be paid in respect of the Finance Documents, choice of law and enforceability of judgments. 

 

	(h)	 A legal enforceability opinion of Arendt & Medernach, addressed to the Bank on the legality, validity
and enforceability of the Finance Fee Letter under Luxembourg law; 

  

	(i)	 A legal opinion of Osborne Clarke Rechtsanwälte Steuerberater Partnerschaft mbB, legal adviser to the
Borrower, addressed to the Bank, and dated no earlier than the date falling [***] days before the Disbursement Date: 

  

	 	(i)	 which includes an insolvency search on www.insolvenzbekanntmachungen.de on the relevant Obligor conducted on
the date of such legal opinion; and 

  

					
		  	Personalised Immunotherapies (EGFF).	  	41

	 	(ii)	 on the valid existence of each Obligor, the authority and capacity of each Obligor to enter into the Finance
Documents and perform its obligations thereunder, non-conflict with constitutional documents and on laws applicable to companies generally in Germany, all corporate and other action required to be taken has
indeed been taken, the due execution of the Finance Documents and that the Obligor is not entitled to claim immunity. 

  

	(j)	 The latest audited financial statements of the Obligors. 

 

	(k)	 Evidence of payment of all the fees (including lawyer fees) and expenses as required under the Finance
Documents. 

  

	(l)	 Evidence satisfactory to the Bank of the fulfilment of the following milestones (the “Credit A
Milestone Events”): 

  

	 	(i)	 achievement of a series B equity raise of at least USD [***] (already achieved at the date of this Contract and
fulfilled); 

  

	 	(ii)	 delivery of a copy of (A) the written completion notification (Fertigstellungsmitteilung) or the
acceptance report (Abnahmeprotokoll) of the new [***] (for the avoidance of doubt, without the [***]); and 

  

	 	(iii)	 granting of the Land Charge, by way of a certified land register excerpt (Grundbuchauszug) for the
Property, evidencing the registration of the Land Charge in favour of the Bank. 

  

	(m)	 A copy of any other document, authorisation, opinion or assurance which the Bank has notified the Borrower is
necessary or desirable in connection with the entry into and performance of, and the transactions contemplated by, the Finance Documents or the validity and enforceability of the same. 

Part B – Credit B Conditions Precedent 
  

	(a)	 Credit A has been fully drawn. 

 

	(b)	 Evidence satisfactory to the Bank of the fulfilment of the following milestones (the “Credit B
Milestone Events”): 

  

	 	(i)	 commencement of three additional clinical trials after the end of H1 2019 (two in phase 1 and one beyond phase
1); 

  

	 	(ii)	 cumulative equity raised in an amount of USD [***] (in addition to the series B equity raise evidenced under
the Credit A Milestone Events); and 

  

	 	(iii)	 conclusion (Vertragsschluss) of one or more new partnership agreements/equity deals since end of H1 2019
with a pharmaceutical company, a biotech company or similar companies of international reputation, or institutions that primarily invest in the area of pharmaceuticals, biotechnology or public health, with combined upfront or initial cash
contributions of at least USD [***]. In the case of equity investments, these are to be in addition to those evidenced under the Credit A Milestone Events and the Credit B Milestone Events (already achieved at the date of this Contract).

 Part C – Guarantor Conditions Precedent 

 

	(a)	 The duly executed Guarantee Agreement or, as applicable, accession letter to the Guarantee Agreement.

  

	(b)	 The constitutional documents of such Guarantor(s). 

  

					
		  	Personalised Immunotherapies (EGFF).	  	42

	(c)	 If applicable, an original of a certificate of incorporation and an encumbrance certificate of the Guarantor(s)
not incorporated or established in Germany (“Non- German Guarantor”) dated no more than [***] Business Days from the date of execution of the Guarantee Agreement or accession letter to the Guarantee Agreement (as applicable) (or any
equivalent document in the jurisdiction of incorporation of such Non-German Guarantor(s)). 

  

	(d)	 A copy of the resolution of the competent body (board of directors, supervisory board (Aufsichtsrat),
administrative body (Verwaltungsrat), advisory board (Beirat) or general meeting of shareholders (Gesellschafterversammlung)) of each Obligor: 

 

	 	(i)	 approving the terms of, and the transactions contemplated by, the Finance Documents to which it is a party as
and duly authorising the execution of the Finance Documents to which it is a party; 

  

	 	(ii)	 duly authorising the relevant signatories to execute the Finance Documents to which it is a party on its
behalf; and 

  

	 	(iii)	 authorising a signatory or signatories, on its behalf, to sign and/or despatch all documents and notices to be
signed and/or despatched by it under or in connection with the Finance Documents to which it is a party. 

  

	(e)	 A certificate of an authorised signatory of the respective Guarantor(s) certifying that each copy document
relating to it specified in Paragraphs (b) to (d) of this Part C of Schedule F is correct, complete and in full force and effect as at a date no earlier than the date of their/its entry into or accession to the Guarantee Agreement, including a
specimen of the signature of each person authorised by the resolution in Paragraph (d) above and, if applicable, confirming that guaranteeing or securing, as appropriate, the Loan would not cause any guarantee, security or similar limit or
restriction binding on it to be exceeded. 

  

	(f)	 A legal opinion of a reputable law firm, addressed to the Bank, on the valid existence of the Guarantor(s), the
authority and capacity of the Guarantor(s) to enter into or accede to the Guarantee Agreement (and execute its/their obligations therein) and on the due execution of the Guarantee Agreement (or the accession letter). 

 

	(g)	 Copies of such documentation and other evidence as the Bank may request to carry out and be satisfied with the
results of all necessary “know your customer” requirements or other checks in relation to the identity of any person that it is required (in order to comply with applicable money laundering laws and regulations) to carry out in relation to
the concerned Guarantor(s). 

  

	(h)	 A copy of any other document, authorisation, opinion or assurance which the Bank has notified the Borrower or
the respective Guarantor is necessary or desirable in connection with the entry into and performance of, and the transactions contemplated by, the Guarantee Agreement or the validity and enforceability of the same. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	43

 Schedule G 

Representations and Warranties 
  

	1.	 Authorisations and Binding Obligations 

 

	 	(a)	 Each Obligor is duly incorporated and validly existing as a corporation or company with limited liability under
the laws of its jurisdiction of incorporation. 

  

	 	(b)	 The place of incorporation or establishment of each Obligor is not (a) a jurisdiction classified by any
Lead Organisation as being weakly regulated and/or weakly supervised and/or non-transparent and/or uncooperative or any equivalent classification used by any Lead Organisation, in connection with activities
such as money laundering, financing of terrorism, tax fraud and tax evasion or harmful tax practices, and/or (b) a jurisdiction that is blacklisted by any Lead Organisation in connection with such activities.1 

  

	 	(c)	 Each Obligor has the power to carry on its business as it is now being conducted and to own its property and
other assets, and to execute, deliver and perform its obligations under the Finance Documents. 

  

	 	(d)	 Each Obligor has obtained all necessary Authorisations in connection with the execution, delivery and
performance of the Finance Documents and in order to lawfully comply with its obligations thereunder, and in respect of the Investment, and all such Authorisations are in full force and effect and admissible in evidence. 

 

	 	(e)	 The execution and delivery of, the performance of each Obligor’s obligations under and compliance with the
provisions of the Finance Documents do not and will not contravene or conflict with: 

  

	 	(i)	 any applicable law, statute, rule or regulation, or any judgement, decree or permit to which it is subject;

  

	 	(ii)	 any agreement or other instrument binding upon it which might reasonably be expected to have a material adverse
effect on its ability to perform its obligations under the Finance Documents; or 

  

	 	(iii)	 any provision of its constitutional documents. 

 

	 	(f)	 The obligations expressed to be assumed by each Obligor in each Finance Document to which it is a party are
legal, valid, binding and enforceable obligations. 

  

	2.	 No default or other adverse event 

 

	 	(a)	 There has been no Material Adverse Change since [***].
(Non-repeating) 

  

	 	(b)	 No event or circumstance which constitutes an Event of Default has occurred and is continuing unremedied or
unwaived. 

  

	1 	 Relevant jurisdictions may be identified on the basis of lists of Lead Organisations, as such lists are
updated, amended or supplemented from time to time, including: jurisdictions with strategic deficiencies in the area of AML-CFT as identified by FATF
 (http://www.fatf-gafi.org/countries/#high-risk);
jurisdictions listed “partially compliant”, “provisionally partially compliant” or “non-compliant” in the OECD Global Forum progress reports/ Global Forum rating (http://www.oecd.org/tax/transparency/GFratings.pdf; http://www.oecd.org/tax/transparency/exchange-of-information-on-request/ratings/); jurisdictions identified in EU delegated regulation
2016/1675 of 14.7.2016 supplementing Directive (EU) 2015/849 as high-risk third countries with strategic deficiencies 

 (http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016R1675); and jurisdictions included in the EU list of non-cooperative jurisdictions for tax purposes (https://ec.europa.eu/taxation_customs/tax-common-eu-list_en). 

  

					
		  	Personalised Immunotherapies (EGFF).	  	44

	3.	 No proceedings 

 

	 	(a)	 No litigation, arbitration, administrative proceedings or investigation is current or to the best of its
knowledge and belief (having made due and careful enquiry) is threatened or pending before any court, arbitral body or agency which has resulted or if adversely determined is reasonably likely to result in a Material Adverse Change, nor is there
subsisting against it or any of its Subsidiaries any unsatisfied judgement or award. (Non-repeating) 

  

	 	(b)	 To the best of its knowledge and belief (having made due and careful enquiry) no material Environmental Claim
has been commenced or is threatened against any Obligor. 

  

	 	(c)	 As at the date of this Contract, no Obligor has taken any action to commence proceedings for, nor have any
other steps been taken or legal proceedings commenced or, so far as the Borrower is aware, threatened against any Obligor for its insolvency, winding up or dissolution, or for any Obligor to enter into any arrangement or compositions for the benefit
of creditors, or for the appointment of an administrator, receiver, administrative receiver, examiner, trustee or similar officer. 

  

	4.	 Security 

It is the sole legal and beneficial owner and has good title to the assets which it charges or purports to charge pursuant to the Security
Documents. At the date of this Contract, no Security exists over the assets of any Group Company other than Permitted Security. 
  

	5.	 Ranking 

  

	 	(a)	 Its payment obligations under this Contract rank not less than pari passu in right of payment with all
other present and future secured and unsubordinated obligations under any of its debt instruments except for obligations mandatorily preferred by law applying to companies generally. 

 

	 	(b)	 No financial covenants have been concluded with any other creditor of any Obligor. 

 

	 	(c)	 No Voluntary Non-EIB Prepayment has occurred. 

 

	6.	 Anti-Corruption 

 

	 	(a)	 Each Obligor is in compliance with all applicable European Union and national legislation, including any
applicable anti-corruption legislation. 

  

	 	(b)	 To the best of its knowledge, no funds invested in the Investment by any Obligor or any other Group Company are
of illicit origin, including products of money laundering or linked to the financing of terrorism. 

  

	 	(c)	 No Obligor is engaged in any Illegal Activities and to the best of the Borrower’s knowledge no Illegal
Activities have occurred in connection with the Investment. (Non-repeating) 

  

	7.	 Accounting and Tax 

 

	 	(a)	 The latest available consolidated and unconsolidated audited accounts of the Borrower and the other Obligors
have been prepared on a basis consistent with previous years and have been approved by its auditors as representing a true and fair view of the results of its operations for that year and accurately disclose or reserve against all the liabilities
(actual or contingent) of the Borrower and the other Obligors, as relevant. 

  

	 	(b)	 The accounting reference date of the Borrower and each Obligor is 31 December. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	45

	 	(c)	 No Obligor is required to make any deduction for or on account of any Tax from any payment it may make under
the Finance Documents, except for withholding tax (Kapitalertragssteuer) which have to be deducted pursuant to Article 4.3(e) (Profit Participation). (Non-repeating) 

 

	 	(d)	 All Tax returns required to have been filed by each Obligor or on its behalf under any applicable law have been
filed when due and contain the information required by applicable law to be contained in them. 

  

	 	(e)	 Each Obligor has paid when due all Taxes payable by it under applicable law except to the extent that it is
contesting payment in good faith and by appropriate means. 

  

	 	(f)	 With respect to Taxes which have not fallen due or which it is contesting, each Obligor is maintaining reserves
adequate for their payment and in accordance, where applicable, with GAAP. 

  

	 	(g)	 Under the laws of the jurisdiction of incorporation of each Obligor, it is not necessary that the Finance
Documents be filed, recorded or enrolled with any court or other authority or that any stamp, registration or similar tax be paid on or in relation to the Finance Documents, or the transactions contemplated by the Finance Documents other than the
official certification (öffentliche Beglaubigung) of the Land Charge Creation Deed (Grundschuldbestellungsurkunde) and payment of related notary fees and the registration of the Land Charge in the land register (Grundbuch)
and payment of the related registration fees. (Non-repeating) 

  

	8.	 Information provided 

 

	 	(a)	 Any factual information provided by any Group Company for the purposes of entering into this Contract and any
related documentation was true and accurate in all material respects as at the date it was provided or as at the date (if any) at which it is stated and continues to be true and accurate in all material respect as at the date of this Contract. (Non-repeating) 

  

	 	(b)	 The Group structure chart is true, complete and accurate in all material respects and represents the complete
corporate structure of the Group as at the date of this Contract, and other than as set out therein the Borrower owns no other equity and/or shares in any other business entity. (Non-repeating)

  

	9.	 No indebtedness 

No Obligor has Indebtedness outstanding other than Permitted Indebtedness. (Non-repeating). 

 

	10.	 No Immunity 

No Obligor, nor any of its assets, is entitled to immunity from suit, execution, attachment or other legal process. 

 

	11.	 Pensions 

The pension schemes for the time being operated by the Obligors (if any) are funded in accordance with their rules and to the extent required
by law or otherwise comply with the requirements of any law applicable in the jurisdiction in which the relevant pension scheme is maintained. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	46

 Schedule H 

General Undertakings 
  

	1.	 Use of Loan 

The Borrower shall use all amounts borrowed by it under the Loan to carry out the Investment. 

 

	2.	 Completion of Investment 

The Borrower shall or shall procure that the Investment is carried out in accordance with the Technical Description as may be modified from
time to time with the approval of the Bank, and complete it by the final date specified therein. 
  

	3.	 Procurement procedure 

The Borrower shall secure goods and services for the Investment (a) in so far as they apply to it or to the Investment, in accordance with
EU Law in general and in particular with the relevant EU Directives, and (b) in so far as EU Directives do not apply, by procurement procedures which conform to the relevant requirements set out in the Bank’s “Guide to Procurement for
projects financed by the EIB (2018)”. 
  

	4.	 Compliance with laws 

Each Obligor shall comply in all respects with all laws and regulations to which it or the Investment is subject. 

 

	5.	 Environment 

The Borrower shall: 
  

	 	(a)	 implement and operate the Investment in compliance with Environmental Law; 

 

	 	(b)	 obtain, maintain and comply with requisite Environmental Approvals for the Investment, 

and upon becoming aware of any breach of this Paragraph 5 (Environment): 

 

	 	(i)	 the Borrower shall promptly notify the Bank; 

 

	 	(ii)	 the Borrower and the Bank will consult for up to [***] Business Days from the date of notification with a view
to agreeing the manner in which the breach should be rectified; and 

  

	 	(iii)	 the Borrower shall remedy the breach within [***] Business Days of the end of the consultation period.

  

	6.	 Integrity 

The Borrower shall take, within a reasonable timeframe, appropriate and legally permissible measures in respect of any member of its management
bodies who has been convicted by a final and irrevocable court ruling of an Illegal Activity perpetrated in the course of the exercise of his/her professional duties, in order to ensure that such member is excluded from any Borrower’s activity
in relation to the Loan or the Investment. 
  

	7.	 Disposal of assets 

 

	 	(a)	 Except as provided under Paragraph (b) below, the Borrower shall not, and shall procure that no Group
Company shall, either in a single transaction or in a series of transactions whether related or not and whether voluntarily or involuntarily dispose of all or any part of any Group Company’s business, undertaking or assets (including any
shares, real estate or security of any entity or a business or undertaking, or any interest in any of them). 

  

					
		  	Personalised Immunotherapies (EGFF).	  	47

	 	(b)	 Sub-Paragraph (a) above does not apply to any such disposal
(“Permitted Disposal”): 

  

	 	(i)	 made with the prior written consent of the Bank; 

 

	 	(ii)	 made on arm’s length terms in the ordinary course of business of a Group Company; 

 

	 	(iii)	 made on arm’s length terms and at fair market value for cash, which is reinvested in assets of comparable
or superior type, value and quality; 

  

	 	(iv)	 made on arm’s length terms in exchange for other assets (other than shares, businesses and real estate)
comparable or superior as to type, value and quality; 

  

	 	(v)	 by (A) one Obligor to another Obligor, or (B) a group Company which is not an Obligor to another
Group Company which is not an Obligor; 

  

	 	(vi)	 constituted by a licence of Intellectual Property Rights on arm’s length terms in the ordinary course of
business of a Group Company; 

  

	 	(vii)	 made in relation to non-material assets which have depreciated to less
than [***] of their initial value or which are obsolete; 

  

	 	(viii)	 excluding any disposal otherwise permitted under (ii) to (vii) above, disposals where the higher of the
market value or consideration receivable for such disposals does not exceed EUR [***] over the lifetime of this Contract; or 

  

	 	(ix)	 arising as a result of Permitted Security. 

 

	 	(c)	 A disposal shall in each case only qualify as Permitted Disposal within the meaning of paragraph
(b) above, if the relevant disposal is not of assets forming part of the Investment or shares in subsidiaries holding assets forming part of the Investment, which may not be disposed of unless either (i) such disposal is made in accordance
with Paragraph (b)(vi) above, (ii) the Borrower consults the Bank in relation to such disposal, and the Bank approves such disposal (such approval not to be unreasonably withheld), or (iii) the proceeds of such disposal are applied to
prepay the Bank in accordance with Article 5.3.4 (Disposals). 

 For the purposes of this Paragraph 7 (Disposal
of assets), “dispose” and “disposal” includes any act effecting sale, transfer, lease or other disposal (Verfügung). 
  

	8.	 Maintenance of assets 

The Borrower shall maintain, repair, overhaul and renew all assets required in relation to the Investment as required to keep such assets in
good working order (ordinary wear and tear excepted). 
  

	9.	 Insurances 

The Borrower shall, and shall procure that each Group Company shall, maintain insurances on and in relation to its business and assets with
reputable underwriters or insurance companies against those risks and to the extent as is usual for companies carrying on the same or substantially similar business. 
  

	10.	 Change in business 

The Borrower shall procure that no substantial change is made to the general nature business of the Borrower or the Group as a whole from that
carried on at the date of this Contract. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	48

	11.	 Merger 

The Borrower shall not, and shall procure that no Group Company shall, enter into any amalgamation, demerger, merger or corporate
reconstruction (including the conclusion of any domination and/or profit and loss transfer agreements (Beherrschungs- und/oder Gewinnabführungsverträge) or any other enterprise agreements (Unternehmensverträge)
with the meaning of section 291 AktG) unless: 
  

	 	(a)	 with the prior written consent of the Bank; or 

 

	 	(b)	 such amalgamation, demerger, merger or corporate reconstruction does not result in a Material Adverse Change
and is on a solvent basis, and provided that: 

  

	 	(i)	 only Group Companies are involved and if a Guarantor is involved, the surviving entity will also be or become a
Guarantor; 

  

	 	(ii)	 the resulting entity will not be incorporated or located in a country which is in a jurisdiction that is
blacklisted by any Lead Organisation in connection with activities such as money laundering, financing of terrorism, tax fraud and tax evasion or harmful tax practices as such blacklist may be amended from time to time; and 

 

	 	(iii)	 if the Borrower is involved, (A) the rights and obligations of the Borrower under this Contract will
remain with the Borrower, (B) the surviving entity will be the Borrower and the statutory seat of the Borrower would not as a result of such merger be transferred to a different jurisdiction, (C) the merger will not have an effect on the
validity, legality or enforceability of the Borrower’s obligations under this Contract; and (D) all of the business and assets of the Borrower are retained by it; or 

 

	 	(c)	 the enterprise value of the company (including any Indebtedness remaining in such company) involved in an
amalgamation, demerger, merger or corporate reconstruction not already permitted under Paragraph (b) above (i) does not exceed an amount of EUR [***] in a single transaction and EUR [***] during the Term of the Credit and (ii) provided
Paragraphs (b)(ii) and (iii) above are fulfilled. 

  

	12.	 Books and records 

Each Obligor shall ensure that it has kept and will continue to keep proper books and records of account, in which full and correct entries
shall be made of all financial transactions and its assets and business, including expenditures in connection with the Investment, in accordance with GAAP as in effect from time to time. 

 

	13.	 Ownership 

  

	 	(a)	 The Borrower shall maintain more than 50% (fifty per cent.) of the share capital, directly or indirectly, of
each of its Material Subsidiaries, unless a prior written consent of the Bank is received by the Borrower. 

  

	 	(b)	 The Borrower shall in aggregate maintain not less than 100% (one hundred per cent.) of the share capital,
directly or indirectly, of each Guarantor and each Material Subsidiary, unless: 

  

	 	(i)	 the percentage of the share capital in the relevant Guarantor or Material Subsidiary at the date of this
Contract is lower than 100% (one hundred per cent.) (“Initial Ownership Stake”), in which case the Borrower shall maintain such Initial Ownership Stake; or 

 

	 	(ii)	 prior written consent of the Bank is received by the Borrower. 

 

	 	(c)	 The Borrower shall immediately notify the Bank in the event of a new entity becoming a Subsidiary of the
Borrower through any means, including but not limited to acquisition, creation and spin-off. 

  

	 	(d)	 The undertakings in Sub-Paragraphs (a), (b) and (c) above shall be
calculated in accordance with GAAP as applied by the Borrower on the date of this Contract and as GAAP is amended from time to time and tested annually. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	49

	14.	 Acquisitions 

The Borrower shall not, and shall procure that no Group Company shall, invest in (including by way of payment into the capital reserve
(Kapitalrücklage)) or acquire any entity or a business going concern or an undertaking (whether whole or substantially the whole of the assets or business), or any division or operating unit thereof, or any shares or securities of any
entity or a business or undertaking (or in each case, any interest in any of them) (or agree to any of the foregoing), save for an acquisition or investment: 
  

	 	(a)	 with the prior written consent of the Bank; 

 

	 	(b)	 by one Obligor of an asset sold, leased, transferred or otherwise disposed of by another Obligor;

  

	 	(c)	 by a Group Company of all the shares or other ownership interests in any limited liability company or
corporation, limited liability partnership or any equivalent company, provided that: 

  

	 	(i)	 such entity has not yet commenced commercial operations; 

 

	 	(ii)	 such entity is incorporated in a country that is a member of either or both of the European Union or the
Organisation of Economic Co-Operation and Development; and 

  

	 	(iii)	 no Event of Default is continuing on the date the relevant acquisition agreement is entered into or would occur
as a result of the acquisition; or 

  

	 	(d)	 of shares or other ownership interests in any limited liability company or corporation, limited liability
partnership or any equivalent company, the consideration for which does not exceed an aggregate amount of (x) EUR [***] during any financial year, and (y) EUR [***] during the term of the Credit, provided that: 

 

	 	(i)	 no Event of Default is continuing on the date the relevant acquisition agreement is entered into or would occur
as a result of the acquisition; 

  

	 	(ii)	 the acquired entity is engaged in a business similar or complementary to the business carried on by the Group
as at the date of this Contract; 

  

	 	(iii)	 the acquired entity is not incorporated or located in a jurisdiction that is blacklisted by any Lead
Organisation in connection with activities such as money laundering, financing of terrorism, tax fraud and tax evasion or harmful tax practices as such blacklist may be amended from time to time; 

 

	 	(iv)	 in respect of any acquisition where the consideration exceeds EUR [***], legal and financial due diligence
reports (including customary reliance letters in favour of the Bank) and a business plan (in the form of the most recent budget adjusted for the expected effects of the acquisition) in respect of the [***] next following financial years and any
other due diligence reports received in connection with the acquisition (if any) are provided to the Bank; and 

  

	 	(v)	 the Borrower provides a Compliance Certificate for the [***] month financial periods immediately following the
acquisition, updated on a pro forma basis as if the acquisition has occurred. 

  

	 	(e)	 In relation to Paragraph (d) above the Parties agree, that if: 

 

	 	(i)	 the EBITDA of the Borrower is positive for the Relevant Period ending on the most recent Semi-Annual Date prior
to that acquisition or investment; and 

  

	 	(ii)	 the revenues of the Borrower exceed EUR [***], (together the “Replacement Conditions”), the
threshold included: 

  

	 	(i)	 in Paragraph (d)(x) above will be replaced by a threshold of “[***]% of the Total Assets during any
financial year”; and 

  

					
		  	Personalised Immunotherapies (EGFF).	  	50

	 	(ii)	 in Paragraph (d)(y) above will be replaced by a threshold of “[***]% of the Total Assets during the term
of the Credit “, 

 (together the “Replaced Thresholds”), whereby (x) the amounts of already
done acquisitions or investments permitted under Paragraphs (a) to (d) above shall count towards the Replaced Thresholds and (y) to the extent and for so long as the Borrower complies with the Replacement Conditions. In case the Borrower
does not further comply with any of the Replacement Conditions, the thresholds included in Paragraph (d)(x) and (d)(y) above shall apply again and the Borrower shall use its reasonable best efforts to comply with such thresholds within a reasonable
timeframe. 
 The Borrower shall provide evidence satisfactory to the Bank of the fulfilment of the Replacement Conditions and compliance
with the Replacement Conditions upon demand of the Bank. 
  

	15.	 Indebtedness 

The Borrower shall not, and shall procure that no other Group Company shall, incur any Indebtedness, save for any Existing Indebtedness and
Indebtedness (“Permitted Indebtedness”): 
  

	 	(a)	 incurred with the prior written consent of the Bank; 

 

	 	(b)	 incurred under this Contract; 

 

	 	(c)	 under Permitted Hedging; 

 

	 	(d)	 in respect of a Permitted Guarantee; 

 

	 	(e)	 owing by an Obligor to another Obligor; 

 

	 	(f)	 unsecured Indebtedness to trade creditors and, in respect of the German trade creditors, Indebtedness secured
by customary retention of title arrangements (Eigentumsvorbehalte) incurred in the ordinary course of day-to-day business; or 

 

	 	(g)	 not permitted by the preceding Sub-Paragraphs and the outstanding
amount of indebtedness (including drawn down EIB debt and other existing outstanding interest-bearing liabilities) which does not exceed 2x the last 12 months EBITDA. 

 

	16.	 Guarantees 

  

	 	(a)	 The Borrower shall not, and shall procure that no other Group Company shall, issue or allow to remain
outstanding any guarantees or sureties (Bürgschaften) in respect of any liability or obligation of any person save for: 

  

	 	(i)	 any guarantee or surety (Bürgschaft) under any Security Document or with the prior written consent
of the Bank; or 

  

	 	(ii)	 guarantees or sureties (Bürgschaften) issued by any Group Company under or in connection with:

  

	 	(1)	 under any negotiable instruments in the ordinary course of trade; 

 

	 	(2)	 in connection with any performance bond in the ordinary course of trade; 

 

	 	(3)	 in connection with any Permitted Indebtedness; 

 

	 	(4)	 issued by one Obligor to another Obligor; 

 

	 	(5)	 any bank guarantee issued the benefit of a contractor in connection with construction work to secure such
contractor’s claims (Bauhandwerkersicherung); 

  

	 	(6)	 any guarantee created or subsisting in order to comply with Section 8a of the German Altersteilzeitgesetz
(AltTZG) or pursuant to Section 7e of the German Social Law Act No. 4 (Sozialgesetzbuch IV); or 

  

					
		  	Personalised Immunotherapies (EGFF).	  	51

	 	(7)	 any guarantees or sureties (Bürgschaften) not permitted by the preceding Sub-Paragraphs and the outstanding amount of which does not exceed EUR [***] (or its equivalent) in aggregate for the Group at any time. If and for so long as the Borrower fulfils the Replacement Conditions prior to
issuing the guarantee or surety (Bürgschaft), the threshold amount of EUR [***] increases to EUR [***]. In case the Borrower does not further comply with any of the Replacement Conditions, the threshold of EUR [***] shall apply again and
the Borrower shall use its reasonable best efforts to comply with such threshold within a reasonable timeframe. 

  

	 	(b)	 The Borrower shall procure that, as soon as any Group Company becomes a Material Subsidiary (as identified in
any accounts delivered to the Bank from time to time pursuant to Paragraph 2 (Information concerning the Borrower) of Schedule I (Information and Visits), that Group Company shall promptly notify the Bank and on the Bank’s request
enter into a Guarantee Agreement and provide the Bank with the documentary conditions precedent (each in form and substance satisfactory to the Bank) listed in Part C of Schedule F (Guarantor Conditions Precedent) within [***] Business Days
following the date on which such Group Company qualifies as a Material Subsidiary. 

  

	17.	 Hedging 

The Borrower shall not, and shall procure that no other Group Company shall, enter into any derivative transaction other than Permitted
Hedging, where “Permitted Hedging” means: 
  

	 	(a)	 any derivative transaction entered into by a Group Company with the prior written consent of the Bank;

  

	 	(b)	 any derivative transaction by a Group Company to hedge actual or projected exposure arising in the ordinary
course of trading and not for speculative purposes; and 

  

	 	(c)	 any derivative instrument of a Group Company which is accounted for on a hedge accounting basis but is not
entered into for speculative purposes. 

  

	18.	 Restrictions on distributions 

The Borrower shall not, and shall procure that no other Group Company shall, declare or distribute dividends, or return or purchase shares,
save for: 
  

	 	(a)	 with the prior written consent of the Bank; 

 

	 	(b)	 payments to a Group Company as a result of a solvent liquidation or reorganisation of a Group Company which is
not an Obligor; and 

  

	 	(c)	 any dividend payments made by any Subsidiary. 

 

	19.	 Restrictions on loans 

The Borrower shall not, and shall ensure that no other member of the Group will, be a creditor in respect of any Indebtedness, save for: 

 

	 	(a)	 with the prior written consent of the Bank; 

 

	 	(b)	 any trade credit extended by any member of the Group to its customers on normal commercial terms and in the
ordinary course of its trading activities; 

  

	 	(c)	 any loan made by one member of the Group (other than an Obligor) to another member of the Group;

  

	 	(d)	 a loan made by one Obligor to another Obligor; 

 

	 	(e)	 a loan made by one Obligor to a member of the Group (other than an Obligor) not exceeding an amount of EUR
[***] during the Term of the Credit; or 

  

	 	(f)	 any other Indebtedness or loan advanced to or made available by any member of the Group with the prior written
consent of the Bank. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	52

	20.	 Restrictions on intercompany loans 

The Borrower shall not, and shall procure that no other Group Company shall, make any payment in respect of any intercompany loan, save for:

  

	 	(a)	 with the prior written consent of the Bank; 

 

	 	(b)	 where the lender of the intercompany loan is the Borrower or an Obligor; or 

 

	 	(c)	 the payments to a Group Company as a result of a solvent liquidation or reorganisation of a Group Company which
is not an Obligor. 

  

	21.	 Intellectual Property Rights 

The Borrower shall, and shall procure that each other Group Company shall, (i) obtain, safeguard and maintain its rights with respect to
the Intellectual Property Rights required for the implementation of the Investment in accordance with this Contract, including complying with all material contractual provisions and that the implementation of the Investment in accordance with this
Contract will not result in the infringement of the rights of any person with regard to the Intellectual Property Rights and (ii) ensure that any Intellectual Property Rights required for the implementation of the Investment will be owned by or
licensed to the Borrower, and where such Intellectual Property Rights which are owned by a Group Company are capable of registration, are registered to such party. 
  

	22.	 Maintenance of Status 

The Borrower shall, and shall procure that each other Group Company shall, remain duly incorporated and validly existing as a corporate entity
with limited liability under the jurisdiction in which it is incorporated and that it will have no centre of main interests, permanent establishment or place of business outside the jurisdiction in which it is incorporated, and that it will continue
to have the power to carry on its business as it is now being conducted and continue to own its property and other assets. 
  

	23.	 Negative pledge 

 

	 	(a)	 The Borrower shall not (and shall procure that no other Group Company shall) create or permit to subsist any
Security over any of its assets. 

  

	 	(b)	 For the purposes of this Paragraph 23 (Negative pledge), the term Security shall also include any
arrangement or transaction on assets or receivables or money (such as the sale, transfer or other disposal of assets on terms whereby they are or may be leased to or re-acquired by any Group Company, the sale,
transfer or other disposal of any receivables on recourse terms or any arrangement under which money or the benefit of a bank account or other account may be applied or set off or any preferential arrangement having a similar effect) in
circumstances where the arrangement or transaction is entered into primarily as a method of raising credit or of financing the acquisition of an asset. 

  

	 	(c)	 Sub-Paragraph (a) above does not apply to any Existing Security
and any Security, listed below (“Permitted Security”): 

  

	 	(i)	 any Security created under the Security Documents in favour of the Bank; 

 

	 	(ii)	 any netting or set-off arrangement entered into by any Group Company in
the ordinary course of its banking arrangements for the purpose of netting debit and credit balances and any Security arising under general business conditions (Allgemeine Geschäftsbedingungen) of banks or financial institutions;

  

					
		  	Personalised Immunotherapies (EGFF).	  	53

	 	(iii)	 any payment or close out netting or set-off arrangement pursuant to any
Permitted Hedging, but excluding any Security under a credit support arrangement in relation to a hedging transaction; 

  

	 	(iv)	 any Security arising by operation of law and in the ordinary course of trading; 

 

	 	(v)	 any Security over or affecting any asset acquired by Group Company after the date of this Contract if:

  

	 	(1)	 the Security was not created in contemplation of the acquisition of that asset by a Group Company;

  

	 	(2)	 the principal amount secured has not been increased in contemplation of or since the acquisition of that asset
by a Group Company; and 

  

	 	(3)	 the Security is removed or discharged within [***] months of the date of acquisition of such asset;

  

	 	(vi)	 any Security over or affecting any asset of any company which becomes a Group Company after the date of this
Contract, where the Security is created prior to the date on which that company becomes a Group Company, if: 

  

	 	(1)	 the Security was not created in contemplation of the acquisition of that company; 

 

	 	(2)	 the principal amount secured has not increased in contemplation of or since the acquisition of that company;
and 

  

	 	(3)	 the Security is removed or discharged within [***] months of that company becoming a Group Company;

  

	 	(vii)	 any Security entered into pursuant to this Contract; 

 

	 	(viii)	 any Security arising under any retention of title (including extended retention of title (verlängerter
Eigentumsvorbehalt)), hire purchase or conditional sale arrangement or arrangements having similar effect in respect of goods supplied to a Group Company in the ordinary course of trading and on the supplier’s standard or usual terms and
not arising as a result of any default or omission by any Group Company; 

  

	 	(ix)	 in respect of the Property to the extent restrictions on further charges are prohibited by Section 1136
BGB; 

  

	 	(x)	 in respect of the Property interests, rights, easements or other matter whatsoever evidenced in section II of
the land register (Grundbuch) as reflected in the copy of the land register excerpt (Grundbuchauszug) provided to the Bank; 

  

	 	(xi)	 any Security created or subsisting in order to comply with Section 8a of the German Altersteilzeitgesetz
(AltTZG) or pursuant to Section 7e of the German Social Law Act No. 4 (Sozialgesetzbuch IV); 

  

	 	(xii)	 any contractor’s lien arising by operation of law (Werkunternehmerpfandrecht) in connection with
repairs and maintenance work and any landlord’s pledge (Vermieterpfandrecht) arising by operation of law under a lease in favour of the relevant third party landlord; or 

 

	 	(xiii)	 any Security securing indebtedness the principal amount of which (when aggregated with the principal amount of
any other indebtedness which has the benefit of Security given by a Group Company other than any permitted under sub-paragraphs (i) to (xii) above) does not exceed EUR [***] during the term of this
Credit. In relation to this Paragraph (xiii) the Parties agree, that if and for so long as the Borrower fulfils the Replacement Conditions prior to providing the security, the threshold in this Paragraph (xiii) will be replaced by a threshold
constituting the lesser of (A) [***]% of the Total Assets during any financial year, and (B) EUR [***]. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	54

	24.	 Other Undertakings 

The Borrower shall take note of the Bank’s group statement on tax fraud, tax evasion, tax avoidance, aggressive tax planning, money
laundering and financing of terrorism (as published on the Bank’s website and as may be amended from time to time). 
  

	25.	 Clauses by inclusion 

If the Borrower or any Group Company concludes with any other secured and unsubordinated creditor a financing agreement that includes a loss-of-rating clause or a covenant or other provision regarding its financial ratios, if applicable, that is not provided for in this Contract or is more favourable to the
relevant creditor than any equivalent provision of this Contract is to the Bank, the Borrower shall promptly inform the Bank and shall provide a copy of the more favourable provision to the Bank. The Bank may request that the Borrower promptly
executes an agreement to amend this Contract so as to provide for an equivalent provision in favour of the Bank. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	55

 Schedule I 

Information and Visits 
  

	1.	 Information concerning the Investment 

Subject to Paragraph 5 below: 
  

	 	(a)	 The Borrower shall deliver to the Bank: 

 

	 	(i)	 the information in content and in form, and at the times, specified in Part A.2 (Information Duties) of
Schedule A (Investment Specification and Reporting) or otherwise as agreed from time to time by the parties to this Contract; 

  

	 	(ii)	 any such information or further document concerning the Investment as the Bank may require to comply with its
obligations under the EFSI Regulation; and 

  

	 	(iii)	 any such information or further document concerning the financing, procurement, implementation, operation and
environmental matters of or for the Investment as the Bank may reasonably require within a reasonable time; 

 provided
always that if such information or document is not delivered to the Bank on time, and the Borrower does not rectify the omission within a reasonable time set by the Bank in writing, the Bank may remedy the deficiency, to the extent feasible, by
employing its own staff or a consultant or any other third party, at the Borrower’s expense and the Borrower shall provide such persons with all assistance necessary for the purpose. 

 

	 	(b)	 The Borrower shall submit for the approval of the Bank without delay any material changes to the Investment,
also taking into account the disclosures made to the Bank in connection with the Investment prior to the signing of this Contract, in respect of, inter alia, the total cost, plans, timetable or to the expenditure programme or financing plan for the
Investment. 

  

	 	(c)	 The Borrower shall promptly inform the Bank of: 

 

	 	(i)	 any action initiated or any objection raised by any third party or any genuine complaint received by the
Borrower or any Environmental Claim that is to its knowledge commenced, pending or threatened against it with regard to environmental or other matters affecting the Investment; and 

 

	 	(ii)	 any fact or event known to the Borrower, which may substantially prejudice or affect the Borrower’s
ability to execute the Investment; 

  

	 	(iii)	 a genuine allegation, complaint or information with regard to Illegal Activities related to the Loan and/or the
Investment; 

  

	 	(iv)	 any non-compliance by it with any applicable Environmental Law; and

  

	 	(v)	 any suspension, revocation or modification of any Environmental Approval, 

and set out the action to be taken with respect to such matters; 
  

	 	(d)	 If the total cost of the Investment exceeds the estimated figure set out in Recital (A), the Borrower shall
notify the Bank without delay and shall inform the Bank of its plans to fund the increased costs. 

  

	 	(e)	 The Borrower shall, and shall procure that each other Group Company shall, promptly inform the Bank if at any
time it becomes aware of the illicit origin (including products of money laundering or linked to the financing of terrorism) of any funds invested in the Investment by the Borrower or another Group Company. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	56

	 	(f)	 The Borrower shall provide to the Bank, if so requested: 

 

	 	(i)	 a certificate of its insurers showing that all assets required in order to carry out the Investment are insured
with reputable underwriters or insurance companies against those risks and to the extent as is usual for companies carrying on the same or substantially similar business; and 

 

	 	(ii)	 annually, a list of policies in force covering any aspect of the Investment, together with confirmation of
payment of the current premiums. 

  

	2.	 Information concerning the Borrower 

Subject to Paragraph 5 below: 
  

	 	(a)	 The Borrower shall deliver to the Bank: 

 

	 	(i)	 as soon as they become available but in any event within [***] months after the end of each of its financial
years its audited consolidated and unconsolidated annual report, balance sheet, cash flow statement, profit and loss account and auditors report for that financial year (the “Approved Financial Statements”) together with a
Compliance Certificate signed by 2 (two) directors (Vorstände) and the unconsolidated financial statements (audited, if available) of each Obligor for such financial year; 

 

	 	(ii)	 as soon as they become available but in any event within [***] months after the end of each of the relevant
accounting periods its interim consolidated and unconsolidated semi-annual report, balance sheet, profit and loss account and cash flow statement for the first half-year of each of its financial years together with a Compliance Certificate signed by
[***] directors (Vorstände); 

  

	 	(iii)	 from time to time, such further information, evidence or document concerning its general financial situation or
such certificates of compliance with the undertakings of Article 7 (Borrower undertakings and representations) as the Bank may reasonably deem necessary or may reasonably require to be provided within a reasonable time; 

 

	 	(iv)	 any such information or further document concerning customer or any other type of due diligence matters of, or
for, the Borrower or the Group, including without limitation to comply with “Know your customer” (KYC) or similar identification procedures as the Bank may deem necessary or may reasonably require to be provided within a reasonable time;
and 

  

	 	(v)	 from time to time, such further information, evidence or document concerning the factual information or
documents provided to the Bank for the purposes of entering into this Contract, as the Bank may deem necessary or may require to be provided within a reasonable time. 

 

	 	(b)	 The Borrower shall deliver to the Bank as soon as possible but in any event within [***] days after the start
of each half-year a budget for that half-year (“Budget”). The Borrower shall ensure that each Budget: 

  

	 	(i)	 includes [***]; 

  

	 	(ii)	 is prepared in all material respects in accordance with GAAP and the accounting practices and financial
reference periods applied to the consolidated financial statements of the Group; and 

  

	 	(iii)	 has been approved by Authorised Signatories of the Borrower. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	57

	 	(c)	 the Borrower shall inform the Bank immediately of: 

 

	 	(i)	 any Default or Event of Default having occurred or being threatened or anticipated; 

 

	 	(ii)	 to the extent permitted by law, any material litigation, arbitration, administrative proceedings or
investigation carried out by a court, administration or similar public authority, which, to the best of its knowledge and belief is current, threatened or pending: 

 

	 	(1)	 against any Obligor or its controlling entities or members of the Borrower’s management bodies in
connection with Illegal Activities related to the Loan or the Investment; or 

  

	 	(2)	 which would if adversely determined result in a Material Adverse Change; 

 

	 	(iii)	 to the extent permitted by any law applicable to the Borrower, any measure taken by the Borrower pursuant to
Paragraph 6 (Integrity) of Schedule H (General Undertakings); 

  

	 	(iv)	 any change in the beneficial ownership of the Borrower and any material update of or change to the Budget; and

  

	 	(v)	 any Voluntary Non EIB Prepayment that has occurred or is likely to occur. 

 

	3.	 Visits by the Bank 

 

	 	(a)	 Each Obligor shall allow the Bank and, when either required by the relevant mandatory provisions of EU law or
pursuant to the EFSI Regulation, the competent EU institutions, including the European Court of Auditors, the Commission, the European Anti-Fraud Office, as well as persons designated by the foregoing; 

 

	 	(i)	 to visit during normal business hours with prior notice, except in cases of emergency, the sites, installations
and works comprising the Investment; 

  

	 	(ii)	 to interview representatives of each Obligor, and not obstruct contacts with any other person involved in or
affected by the Investment; and 

  

	 	(iii)	 to conduct such on the spot audits and checks as they may wish and review the Obligors’ books and records
in relation to the execution of the Investment and to be able to take copies of related documents to the extent not prohibited by the law. 

  

	 	(b)	 Each Obligor shall provide the Bank, or ensure that the Bank is provided, with all necessary assistance for the
purposes described in this Paragraph 3 (Visits by the Bank). 

  

	 	(c)	 In the case of a genuine allegation, complaint or information with regard to Illegal Activities related to the
Loan and/or the Investment, the Borrower shall consult with the Bank in good faith regarding appropriate actions. In particular, if it is proven that a third party committed Illegal Activities in connection with the Loan and/or the Investment with
the result that the Loan or the EFSI financing were misapplied, the Bank may, without prejudice to the other provisions of this Contract, inform the Borrower if, in its view, the Borrower should take appropriate recovery measures against such third
party. In any such case, the Borrower shall in good faith consider the Bank’s views and keep the Bank informed. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	58

	4.	 Disclosure and publication 

 

	 	(a)	 The Bank acknowledges and agrees that the Borrower may be obliged to disclose the terms of this Contract and
make any other public written disclosure regarding the existence of, or performance under, this Contract, to the extent required, in the reasonable opinion of BioNTech’s legal counsel, to comply with (i) law, statute or regulation
applicable to the Borrower, including the rules and regulations promulgated by the United States Securities and Exchange Commission or (ii) any equivalent governmental authority, securities exchange or securities regulator in any country shares
of the Borrower are listed. Before disclosing this Contract or any of the terms hereof pursuant to this Paragraph 4(a), the Borrower will inform the Bank with at least [***] Business Days prior notice of the intended disclosure and will consult with
the Bank in making any such disclosure acceptable to the Bank. Further, if the Borrower discloses this Contract or any of the terms hereof in accordance with this Paragraph 4(a), the Borrower will, at its own expense, seek such confidential
treatment of confidential portions of this Contract and limit its disclosure of such terms to that the extent required to comply with law, statute or regulation applicable to the Borrower. 

 

	 	(b)	 The Borrower acknowledges and agrees that: 

 

	 	(i)	 the Bank may be obliged to communicate information relating to any Obligor and the Investment to any competent
institution or body of the European Union in accordance with the relevant mandatory provisions of European Union law or pursuant to the EFSI Regulation; and 

  

	 	(ii)	 the Bank may publish in its website or produce press releases containing information related to the financing
provided pursuant to this Contract with support of the EFSI, including the name, address and country of establishment of the Borrower the purpose of the financing, and the type and amount of financial support received under this Contract.

 To the extent legally and practically possible, the Bank shall communicate and/or publish such information only upon
prior coordination with the Borrower. To the extent the Bank has coordinated such communication/publication with the Borrower, the Borrower will ensure that to the same extent and at the same time such information is made available to the United
States Securities and Exchange Commission. 
  

	 	(c)	 The Borrower agrees to cooperate with the Bank to ensure that any press releases or publications made by the
Borrower regarding the financing and the Investment include an appropriate acknowledgement of the financial support provided by the Bank with the backing of the European Union through EFSI. 

 

	 	(d)	 The Obligors are entitled and, if requested by the Bank, each Obligor undertakes to refer to this financing and
other Bank financings in its public communications, if appropriate, during the availability period, and in connection with any drawdowns, and communications on major corporate events. 

 

	5.	 Confidential information 

Where the Borrower provides information to the Bank in connection with this Contract, it shall clearly indicate whether such information is
already public or being maintained by the Borrower as confidential information. If regulated or prohibited by applicable legislation including the rules and regulations promulgated by the United States Securities and Exchange Commission and
securities law relating to insider dealing and market abuse, the Borrower will not share (and is not obliged to do so) any inside information with the Bank before it is published to the market. For the avoidance of doubt, the Parties agree that the
Borrower shall only be required to provide information to the Bank to the extent legally permissible and in particular in compliance with applicable laws on inside information. The Bank is not responsible or liable for any determination as to
whether any information provided or to be provided to it is non-public information the use of which may be regulated or prohibited by applicable law or regulation relating to insider dealing or otherwise. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	59

 Schedule J 

Existing Indebtedness 
 1.
Indebtedness in connection with a secured EUR 10,000,000 loan agreement dated 21 November 2017 and entered into by BioNTech Innovative Manufacturing Services GmbH as borrower and Deutsche Bank AG as lender. 

2. Indebtedness in connection with a secured EUR 9,450,000 loan agreement dated 18 July 2018 and entered into by JPT Peptide Technologies GmbH as borrower and
Deutsche Bank AG as lender. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	60

 Schedule K 

Existing Security 
  

	1)	 EUR 10,000,000.00 loan agreement dated 21 November 2017 with BioNTech Innovative Manufacturing Services GmbH as
borrower and Deutsche Bank AG as lender. 

  

	 	•	 	 First-priority land charges (Grundschulden) of EUR 10,000,000 on commercial property
(Betriebsimmobilie) in 55743 Idar-Oberstein, Germany, Idar-Oberstein [***], granted by BioNTech Innovative Manufacturing Services GmbH; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]. 

  

	2)	 EUR 9,450,000 loan agreement dated 18 July 2018 with JPT Peptide Technologies GmbH as borrower and Deutsche
Bank AG as lender. 

  

	 	•	 	 First-priority land charges (Grundschulden) of EUR 9,450,000 on commercial property (Betriebsimmobilie)
Berlin-Adlershof; Germany, [***], granted by JPT Peptide Technologies GmbH; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]. 

  

					
		  	Personalised Immunotherapies (EGFF).	  	61

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]